

14 March 2025

John H. Rex, MD, FACP, FIDSA, FECMM, FFPM (Hon.)
john.rex@amr.solutions

PRESENT TITLES:


- Chief Medical Officer, F2G, Ltd., Manchester, United Kingdom
- Editor-in-Chief, AMR.Solutions
- Operating Partner, Advent Life Sciences, London, UK
- Adjunct Professor of Medicine, McGovern Medical School, Houston, TX

GENERAL OVERVIEW:

I am a science-based leader with over 35 years of experience, including:

- 15 years as an **academic investigator** 1987- 2002 (National Institutes of Health, Bethesda, MD; Univ. of Texas Medical School-Houston; pre-clinical translation, clinical investigator; clinical program design; US and EU regulatory interactions).
- **Large pharmaceutical industry experience** 2003-16 at AstraZeneca Pharmaceuticals as VP Clinical Infection (Jan 2003-May 2012) and then Senior VP and Head of Infection, Global Medicines Development (June 2012-Oct 2016).
- **Small pharmaceutical industry experience** at F2G Ltd (Independent Board Director then Chief Medical Officer and Director, Sep 2012-present) and Adenium Biotech ApS (Independent Board Director, Nov 2015-2019).
- **Venture Capital experience** both as an Operating Partner of Advent Life Science (2015-present, a VC based in London) and with multiple successful private VC-based rounds for F2G Ltd.
- **Charitable foundation experience** as Expert-in-Residence at Wellcome Trust (2014-2019).
- **Public-Private partnership** experience as co-founder of the New Drugs For Bad Bugs (**ND4BB**, 2012-17) within EU's Innovative Medicines Initiative (**IMI**), creation of **DRIVE-AB** (2014-2017) within ND4BB for evaluation and implementation of novel antibiotic business models, and Chief Strategy Officer for **CARB-X** (2016- 17).
- **Government advisory experience** via an advisory role during creation of the US National Action Plan for AMR (2014) and then a term as voting member of the US Presidential Advisory Committee on Combatting Antimicrobial Resistance (2015-2019).
- **A track record of driving communication across diverse stakeholders through a newsletter:** AMR.Solutions, active since 2017, and now with > 3000 readers worldwide
- Via these roles, **diverse antibacterial and antifungal development experience in all drug phases (figure).**
- Via these roles, **experience with business development** (six transactions while at AZ, Series E-H for F2G, Ltd).

Commented [JHR1]: ADJUST



GLOBAL IMPACT

The hallmark of my work has been leadership via using knowledge to connect people, create new ideas, and inspire collaboration with a focus on (i) creating pathways to enable development of new antimicrobial agents, (ii) creating actual new antimicrobial agents (figure), (iii) ensuring adequate reimbursement for novel agents, and (iv) thereby ensuring access to novel agents. During my time in Industry, I have held multiple leadership roles for Industry interactions with FDA, EMA, and other external groups with a focus on enhancing available development pathways and the approaches to value for antimicrobial agents. **Three particular areas of contribution have been my focus since the early 2000s:**

14 March 2025

First, I have had experience with regulatory interactions including **paradigm-changing work on registration pathways for novel antibacterial and antifungal agents** in settings where only limited data can be generated: Key papers include:

- Rex JH et al. Proposal for a comprehensive regulatory framework to address the unmet need for new antibacterial therapies. *The Lancet Infectious Diseases* 13 (3):269 - 275, **2013**.
- McDonnell AM, Rex JH, Goossens H, Bonten M, Fowler VG, Dane A. Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. *Clinical Infectious Diseases*. **2016**;63 (Suppl. 2):S57-59.
- Rex, JH, et al. Progress in the fight against multidrug-resistant bacteria 2005-2016: Modern non-inferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. *Clinical Infectious Diseases* 65: 141-146, **2017**.
- Rex, JH, et al. Designing development programs for non-traditional antibacterial agents. *Nature Communications* 10: 3416, **2019**.

Second, my roles have given me **experience with changing the development and reimbursement environment for antimicrobial agents** (including a role on the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria). Key papers include:

- Rex JH, Outterson, K. Antibiotic Reimbursement in a Sales-Delinked Model: Context and a Benchmark-Based Global Approach. *The Lancet Infectious Diseases* 16:500-505, **2016**.
- Outterson K, Rex JH. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. *Translational Research*. DOI: <https://doi.org/10.1016/j.trsl.2020.02.006>, **2020**.
- Rex JH, Outterson, K. Antibacterial R&D at a crossroads: We've pushed as hard as we can ... now we need to start pulling!" *Clinical Infectious Diseases* <https://doi.org/10.1093/cid/ciaa852>, **2020**.
- Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex J, and Sumpradit N. Antibiotic development – economic, regulatory and societal challenges. *Nat Rev Microbiol* 18, 267–274, **2020**.
- Outterson K, Orubu ESF, Rex JH, Ardal C, Zaman MH, Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020. *Clin Infect Dis*. **2021** Jul 12:ciab612. doi: 10.1093/cid/ciab612.
- Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. *Clin Infect Dis*. **2021** May 4;72(9):e420-e421. doi: 10.1093/cid/ciaa092. PMID: 31999818.
- Outterson K, Rex JH. Global Pull Incentives for Better Antibacterials: The UK Leads the Way. *Appl Health Econ Health Policy*. **2023** May;21(3):361-364. doi: 10.1007/s40258-023-00793-w. Epub 2023 Feb 11. PMID: 36773115; PMCID: PMC10119039

Finally, I seek to use knowledge to connect, create, and inspire through my newsletter (<https://amr.solutions/>) and an associated YouTube channel. The newsletter currently has > 3,000 readers worldwide.

Training and work experience (abbreviated)

- 1975-1987, Core training: Earned a BA (Rice University, Houston, Texas), an MD (Baylor College of Medicine, Houston, Texas), and completed an Internal Medicine residency (Stanford University Hospital).
- 1987-2002, Academic ID experience: Fellowship in Infectious Diseases (NIAID, NIH) and academic faculty appointment, culminating in a role as Professor of Medicine (University of Texas Medical School-Houston) and 5 years of experience as the hospital epidemiologist for Memorial Hermann Hospital.
- 2003-2016 (October), Large pharma experience: A series of VP-level roles at AstraZeneca Pharmaceuticals, culminating in the sale of the AZ business unit to Pfizer.
- 2012- present, Small pharma, venture capital, charity, and public-private partnership experience: By agreement with AstraZeneca, my work during 2012-2016 (October) overlapped with a selected number of non-conflicting external roles in small pharma, a VC firm, a charity (Wellcome Trust), and a public-private partnership (CARB-X). Since the AstraZeneca-Pfizer sale, I have continued the small pharma, ventural capital, charity, and public-private partnership work begun in 2012.

14 March 2025

EXTENDED CV

WORK HISTORY

2012 to present: Non-Executive (Independent) Director (2012 to 2016), then Chief Medical Officer and Director (2016 to 2021), F2G, Ltd., and Chief Medical Officer (2021 to present), F2G, Ltd.

F2G, based in Manchester in the UK, is an antifungal drug discovery and development company dedicated to finding new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. Currently F2G is advancing its F3 series of anti-mould compounds. This is a novel class of antifungal agent, which acts through a completely new mechanism different from all currently marketed drugs. The F3 series displays highly potent activity against clinically relevant *Aspergillus* species and many other important pathogenic moulds.

Responsibilities:

- Active participation in F2G governance and strategic decisions.
- Active involvement in fund-raising and licensing, including a licensing arrangement announced 2022 with Shionogi & Co., Ltd, with an upfront of \$100m, milestones of up to \$380m, and royalty.
- Active & direct review and guidance of compound progression via the Board's Science Committee (Sep 2012 to Oct 2016) and then as Chief Medical Officer (Nov 2016 to present).

August 2014 to December 2019: Expert-in-Residence (EIR) and Senior Advisor for Drug-Resistant Infections, Wellcome Trust.

Based in London, UK., Wellcome Trust is one of the world's largest funders of biomedical research. As an EIR at Wellcome, I chair funding committees and serve as an advisor on their funding strategies.

Responsibilities:

- Provide advice on funding strategy and related initiatives.
- As needed, chair workshop and committees.

November 2015 to September 2019: Non-Executive (Independent) Director, Adenium Biotech ApS.

Based in Copenhagen, Denmark, Adenium is dedicated to discovery and development of novel mechanism antibacterial therapies.

Responsibilities:

- Active participation in all Adenium Board meetings and decisions.
- Active & direct review and guidance of compound progression via the Board's Science Committee.

July 2016 to October 2017, Chief Strategy Officer, CARB-X.

Based at Boston University School of Law, CARB-X (www.carb-x.org) is a public-private partnership providing non-equity, non-dilutive finance in support of pre-clinical development of antibacterial products by leveraging \$250 million in US BARDA (Biomedical Advanced Research and Development Authority) funds with matching funds from the Wellcome Trust and the AMR Centre (UK).

Responsibilities:

- Worked with the Executive Director to design the overall portfolio strategy for this project.
- Initiated the CARB-X^{ed} educational initiative in collaboration with GARD-P.

AstraZeneca (Jan 2003 to Oct 2016): An Overview

During my 14-year career at AstraZeneca, I drove a comprehensive Infection-focused and value-oriented program of team- and pipeline-building via multiple approaches to partnership, creative risk sharing, three licensing deals, three acquisitions,

14 March 2025

and internal program progression. With these activities, the AstraZeneca Infection program progressed from having only one product in late life-cycle management in 2003 to a strongly diversified global program featuring six products in clinical development spanning all phases of clinical development, registration, and post-approval commercialization. Key events have included the 2009 registration of CUBICIN in China, the 2012 EU Marketing Authorization of ZINFORO, the 2015 approval of AVYCAZ in the United States, the 2015 co-development agreement with BARDA under its OTA (Other Transactional Authority) for ATM-AVI and a portfolio of other products, and the 2016 approval of ZAVICEFTA in the EU. This body of work concluded in November 2016 with the sale of the antibiotic business unit to Pfizer.

By agreement with AstraZeneca, my work during 2012-2016 overlapped with a selected number of non-conflicting external roles (see above).

November 2015 to October 2016: Senior Vice President and Chief Strategy Officer, Antibiotics Business Unit, AstraZeneca

As Senior VP and Chief Strategy Officer, I reported to the Managing Director of the Antibiotics Business Unit (BU). Work in this role led to the successful sale of the AstraZeneca Antibiotics group to Pfizer during 2H16.

Responsibilities:

- Provide strategic guidance to the BU and its teams.
- Lead business development activities for the BU.
- Manage external policy and regulatory interactions for the BU.

June 2012 to October 2015: Senior Vice President and Head of Infection, Global Medicines Development, AstraZeneca

As Senior VP and Head of Infection, Global Medicines Development (June 2012 to Nov 2015), I reported to the Executive Vice President of Global Medicines Development and had project, budget, and people responsibility for delivery of the Development programs supporting the AstraZeneca Infection pipeline. The role included membership in the Global Medicines Development Leadership Team, the AstraZeneca Portfolio Review Board (the body charged with governance for all late-stage programs), and the AstraZeneca Innovative Medicines Review Board (the body charged with governance for all preclinical and early-stage programs).

Responsibilities:

- Deliver the global late stage portfolio and the Life cycle management programs.
- Vision & direction for portfolio strategy for the area.
- Medical accountability for all programs in the Therapy Area.
- Continuity of the medical view across all phases of development.
- Continuous enhancement of people capabilities needed to support the evolving portfolio.
- Drive the business development opportunities for the Therapy area.
- Line management responsibilities for Development staff.

Jan 2003 through May 2012: Vice President Clinical Infection, AstraZeneca

As Vice President Clinical Infection, Oncology & Infection Therapy Area (2003-2010) and then Vice President Clinical Infection (2010-May 2012), I reported to the Global Vice President for Clinical Development. The role was a matrix-based role that included interactions with the senior AstraZeneca leadership, especially the head of the Oncology & Infection Therapy Area (2003-2010), the head of the Infection Innovative Medicines Unit (2010-2012) and the Executive Vice Presidents for Discovery, Development, and Finance (2003-2012).

Responsibilities:

- Strategic clinical leadership of anti-infective development program.
- Management of clinical evaluation and due diligence for anti-infective licensing opportunities.
- Clinical review of discovery programs with a focus on bridging the discovery and clinical phases.
- Oversight of clinical development program for all phases (Phase 1 to life-cycle management).
- Line management responsibility for Infection-focused physicians and clinical project leaders (growth over time from one to four independent teams comprising 19 FTE as well as ad hoc contractors and consultants).

Commented [JR2]: September

Commented [JR3]: August

Commented [JR4]: February

14 March 2025

- Intra- and inter-therapy area portfolio planning, priority setting, succession planning, and team building.

Major deliverables:

- **Strategic.** Clinical & strategic leadership for AZ Infection as Head of Infection Disease Area Team (2003—2010).
 - Developed an integrated strategy for taking the Infection pipeline from a single marketed product to a pipeline with products in all stages of development.
 - Internal champion for strategy with key stakeholders including the Senior Executive Team.
 - Successful collaborative delivery of strategy including an investment decision to expand the physical footprint of the Discovery facility in Boston (2006), pipeline acceleration via licensing and acquisition (see below), and internal pipeline progression.
 - Shaping of external environment for antibiotic delivery via external interactions regarding the unmet need for antibiotics, guidelines for antibiotic development, and the need for incentives for antibiotics.
- **Development.** Delivery of the pipeline via clinical oversight of development programs:
 - Worldwide marketing program for meropenem (Merrem), including 2004-5 sNDA for complicated skin and soft-tissue infections and growth from ~\$300m/yr to nearly \$900m/yr during 2003-2010).
 - Since 2007, regular progression into first-time-in-man studies of novel antibacterial and antiviral classes based on preclinical resolution of key product challenges and understanding of relevant markers of success in early clinical programs.
 - Progression of licensed/acquired programs through key regulatory interactions (FDA, EMA, Japan PMDA, China SFDA), regulatory filings (INDs or equivalent as needed, EU scientific advice, FDA meetings), and internal investment decision milestones (decisions to invest in FTIM studies, in Phase 2b studies, and Phase 3 studies).
 - (2003-2010) As a member of the Oncology & Infection Therapy Area Portfolio Team, participation in all of the above-described program decisions for the Oncology portfolio with the opportunity to use challenges in one therapy area to inform and guide the other therapy area.
 - (2010-onward) Through support of the Clinical Development Leadership Team and the Infection Innovative Medicines unit, continued build of the people and projects supported by the Infection Therapy Area.
- **Business development.** Building the pipeline via technical leadership (and joint leadership of related business analyses) of multiple licensing reviews, including delivery of:
 - AstraZeneca-Protherics licensing deal for CytoFab (2005)
 - AstraZeneca-Cubist regional (Asia-Pacific) licensing deal for Cubicin (2006)
 - AstraZeneca acquisition of Arrow Therapeutics (2007)
 - AstraZeneca acquisition of MedImmune (2007)
 - AstraZeneca-Forest Pharmaceuticals licensing deal for Ceftaroline (2009)
 - AstraZeneca acquisition of Novexel in collaboration with Forest Pharmaceuticals (2009)

Commented [JHR5]: Internal recognitions. Team Leader of Due Diligence team that won 2004 “Mission, Vision, and Values” award for timely delivery of a complex (3-way) product opportunity review. Merrem marketing & development team won 2004 “Drive the Curve” award for sustained product growth. Merrem development team won 2005 “Collaborate as One Team” award for timely delivery of Merrem sNDA.

Positions & experience prior to taking a full-time Industry role

Pharmaceutical Industry Experience and Activities as an academic investigator:

1992-2002: Academic consultant, clinical trials investigator, design of clinical development programs, and conduct of preclinical studies for fluconazole (Diflucan, Pfizer), voriconazole (Vfend, Pfizer), itraconazole (Sporanox, Janssen / Ortho-Biotech), ravuconazole (Bristol-Meyers Squibb), posaconazole (Schering-Plough), caspofungin (Cancidas, Merck), micafungin (Fujisawa), anidulafungin (Lilly / Versicor / Vicuron), amphotericin B lipid complex (ABLC, The Liposome Company / Enzon), liposomal amphotericin B (AmBisome, Fujisawa / Gilead), and liposomal nystatin (Nyotran, Aronex). Clinical trials investigator for oritavancin (Lilly / Intermune), ertapenem (Invanz, Merck), quinupristin/dalfopristin (Synercid, Aventis), levofloxacin (Levaquin, RW Johnson), linezolid (Zyvox, Pharmacia / Pfizer), and clinafloxacin (Warner-Lambert). Consultant at FDA Advisory Committees for caspofungin and voriconazole. Advisor to, and participant in, preparation of NDA and pre-NDA FDA interactions for voriconazole, caspofungin, micafungin, liposomal nystatin, and anidulafungin.

Academic Appointments:

- Jul 1992–Aug 1996: Assistant Professor of Medicine, University of Texas Medical School at Houston

14 March 2025

- Apr 1994–Aug 1996: Assistant Professor of Medicine, University of Texas M. D. Anderson Cancer Center
- Sep 1996–Aug 2001: Associate Professor of Medicine, University of Texas Medical School at Houston
- Sep 2001–Dec 2002: Professor of Medicine, University of Texas Medical School at Houston
- Jan 2003 to present: Adjunct Professor of Medicine, McGovern Medical School, Houston, Tx

Hospital Appointments:

- Jul 1992–Dec 2002: Medical Staff, Hermann Hospital
- Jul 1992–Dec 2002: Medical Staff, Harris County Hospital District
- Aug 1997–Dec 2002: Medical Director for Epidemiology, Hermann Hospital

Commented [JHR6]: September 2021: Extended another year per correspondence with Dr. Colasurdo (President of UTHSC), see copy of correspondence in folder with CV.

EDITORIAL BOARDS, EDITORSHIPS, ADVISORY BOARDS, AND COMMITTEES:

Editorial Boards (current roles shown in bold)

- 1994–2000 Editorial Board, *Antimicrobial Agents and Chemotherapy*
- 1996–2001 Editorial Board, *Diagnostic Microbiology and Infectious Diseases*
- 1997–present Editorial Board, *Drug Resistance Updates***
- 1997–2020 Editorial Board, *European Journal of Clinical Microbiology & Infectious Diseases*
- 1999–2002 Editorial Board, *Current Opinion in Anti-infective Investigational Drugs*
- 2001–2004 Editorial Board, MD Consult (www.mdconsult.com)
- 2003–2010 Highlights Advisory Board, Nature Reviews Microbiology
- 2020–present Editorial Advisory Board, *Clinical Infectious Diseases***

Commented [JHR7]: Actual stop date unknown — five years presumed but cannot be verified as journal lacks adequate details.

Commented [JHR8]: DRU still active on 26 Jan 2025

Commented [JHR9]: Stop date uncertain: last verified 2019 so using 2020. Noted that I was not on the editorial board in 2023.

Commented [JHR10]: Actual stop date unknown — three years presumed but cannot be verified as online materials lack adequate details. MDconsult was closed down in 2014.

Commented [JR11]: Actual stop date unknown. Last verified Feb 2010.

Commented [JR12]: Invited to join 6 Dec 2019, presume active from Jan 2020. Still active as of 26 Jan 2025

Editorships (current roles shown in bold)

- 1994–1998 Associate Editor, *Medical Mycology* (formerly *Journal of Medical and Veterinary Mycology*)
- 2000–2002 Co-Editor-in-Chief and Founder, www.doctorfungus.org, a non-profit web site devoted to dissemination of information about medical mycology
- 2000–2010 Editor, *Antimicrobial Agents & Chemotherapy* (term ended 30 June 2010)
- 2003–2006 Section Editor for Anti-Infectives, *Current Opinion in Anti-infective Investigational Drugs*
- 2003–present Emeritus Editor, www.doctorfungus.org.**

Advisory Boards:

- 1999–2002: Voriconazole Global Advisory Board, Pfizer Pharmaceuticals
- 1999–2002: Caspofungin Advisory Board (chairman), Merck Research Laboratories
- 1999–2001: Nyotran Advisory Board, Aronex Pharmaceuticals and Abbott Laboratories
- 2000–2002: AmBisome Scientific Advisory Board, Gilead Sciences, Inc.
- 2000–2002: Anidulafungin Scientific Advisory Board, Versicor, Inc.
- 2001–2003: Consultant to the Microbiology Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration
- 2001–2002: Infection Therapy Area Management Board, AstraZeneca Pharmaceuticals

National and International Committees (current roles shown in bold)

- 1993–2002 Member, Antifungal Susceptibility Testing Subcommittee, National Committee for Clinical Laboratory Standards
- 1997–2002 Member, Program Committee for ICAAC, the annual Interscience Conference on Antimicrobial Agents & Chemotherapy sponsored by the American Society for Microbiology
- 2000–2002 Vice-President, International Society for Human and Animal Mycology (ISHAM)
- 2001–2008 Member, Program Committee for ACAR, the Annual Conference on Antimicrobial Resistance sponsored by the National Foundation for Infectious Diseases (NFID)
- 2003–2008 Chair, Antifungal Susceptibility Testing Subcommittee, Clinical Laboratory Standards Institutes (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS])
- 2005–2006 Corresponding Member, Program Committee for 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2006, Nice, Italy), sponsored by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
- 2005–2008 Member, Program Committee Infectious Diseases Society of America annual meeting
- 2006 Advisor, Area Committee on Microbiology, Clinical Laboratory Standards Institutes (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS])

Commented [JHR13]: 1994–2000 Chair, Working Group on Detection of Amphotericin B Resistance, Antifungal Susceptibility Testing Subcommittee, National Committee for Clinical Laboratory Standards

Commented [JHR14]: 2001–2002 Member, Program Committee for the John E. Bennett Forum on Deep Mycoses Study Design

14 March 2025

2006-2007 Member, Program Committee for 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2007, Munich, Germany), sponsored by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

2006-2009 Advisor, M23 Working Group, Clinical Laboratory Standards Institutes (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS])

2007 Voting Member, Area Committee on Microbiology, Clinical Laboratory Standards Institutes (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS])

2007 Consultant to CDC Task Force on *Update of A Public Health Action Plan to Combat Antimicrobial Resistance*. Public Meeting December 12-13, 2007

2007-2011 FDA CDER Anti-Infective Drug Advisory Committee, Industry Representative (term ran 1 Nov 07 to 31 Oct 2011)

2008 Vice-Chair, Area Committee on Microbiology, Clinical Laboratory Standards Institutes (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS])

2009-2012 Chair, Consensus Committee on Microbiology, Clinical Laboratory Standards Institutes (CLSI, formerly National Committee for Clinical Laboratory Standards [NCCLS])

2009-present **Advisor, Antifungal Susceptibility Testing Subcommittee, Clinical Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards)**

2009-2012 Member, Research on Resistance Working Group, Infectious Diseases Society of America

2009-2013 Chair, European Federation of Pharmaceutical Industries and Associations (EFPIA) Antimicrobial Working Group

2010-2011 Abstract Review Committee, European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy.

2010-2012 Member, FDA-sponsored Foundations for the NIH working group on Endpoints for Clinical Trials in Community-Acquired Bacterial Pneumonia and Skin Infections

2011-2012 Abstract Review Committee, European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom

2011-2015 Member and Chair, Wellcome Trust “Seeding Drug Discovery” Funding Committee

Multiple dates Member, PhRMA Antimicrobial Resistance working groups and Limited Duration Key Issues Teams (LD-KITs)

2012-2015 Member, Brookings Council on Antimicrobial Drug Development

2012-2013 Abstract Review Cmte, European Congress of Clinical Microbiology and Infectious Diseases

2012-2018 Member, FDA-sponsored Foundations for the NIH working group on Endpoints for Clinical Trials in Hospital-Associated and Ventilator-Associated Pneumonia

2013-2016 Vice Chair, Consensus Committee on Microbiology, Clinical Laboratory Standards Institute

2013-2016 Member, Nominating Committee, Clinical Laboratory Standards Institutes

2014 Advisor to PCAST, the President’s Council of Advisors on Science and Technology

2015 Member, Organizing Committee for 26-27 Mar 2015 IOM (Institute of Medicine) workshop entitled: Enabling Rapid Response with Medical Countermeasures to Mitigate Risk of Emerging Infectious Diseases: An Institute of Medicine Workshop.

2017 Program committee, 2017 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

2015-2019 Voting Member, US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB)

2018-2021 Program committee, ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

2018-2021 Chair, Novo REPAIR Impact Fund Scientific Advisory Board

2021-present **Chair, AMR Action Fund Scientific Advisory Board**

Commented [JR15]: This date is very approximate – there was no official end – I’ve chosen 2013 as one year after the last truly EFPIA-based workshop with EMA (2012-10-25, 26 EMA addendum workshop). I suppose you could argue for the 2014 PK-PD workshop, but this was really IFPMA-based.

TRAINING:

Advanced Training Courses:

- Recombinant DNA Methodology (18 lecture hours, 20 laboratory hours), June, 1990, Foundation for Advanced Education in the Sciences, National Institutes of Health, Bethesda, MD.

14 March 2025

- Special Topics and Methods in Recombinant DNA Research (18 lecture hours, 20 laboratory hours), July, 1990, Foundation for Advanced Education in the Sciences, National Institutes of Health, Bethesda, MD.
- Statistics for Biomedical Scientists I (6 credits), Fall 1988–Spring 1989, Foundation for Advanced Education in the Sciences, National Institutes of Health, Bethesda, MD.
- Symposium on Techniques in Patient-Oriented Research (18 lecture hours), October 30–November 1, 1992. Sponsored by the University of Texas Southwestern Medical Center at Dallas and the GCRC Program of the National Center for Research Resources, National Institutes of Health.
- Training Course in Hospital Epidemiology (23 lecture hours), October 25-28, 1997. Sponsored by Society for Healthcare Epidemiology of American and Center for Disease Control and Prevention (SHEA/CDC).
- Finance for Directors and Senior Executives, September 15-16, 2008. Helmsley Fraser, London.

Postgraduate Training:

- August 1982 to September 1983: Henry Luce Scholar in Seoul, Korea.
- September 1983 to June 1984: Clinical Associate, Section of Infectious Diseases, The Methodist Hospital, Baylor College of Medicine, Houston, Texas
- July 1984 to June 1987: Resident in Internal Medicine, Stanford University Hospital, Stanford, California
- July 1987 to June 1992: Medical Staff Fellow, Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

Graduate Education:

- August, 1982 — M.D., with Honors, Baylor College of Medicine, Houston, Texas

Undergraduate Education:

- June, 1979 — B.A., summa cum laude, Phi Beta Kappa, Rice University, Houston, Texas

LICENSURE, CERTIFICATIONS, HONORS AND AWARDS, PROFESSIONAL ORGANIZATIONS:

Licensure:

- Texas State Board of Medical Examiners, License No. G8957, licensed December, 1985

Certification:

- American Board of Internal Medicine, 1987, Time-Unlimited Certificate Number 115189.
- American Board of Internal Medicine (Infectious Diseases), 1990-2000, Time-Limited Certificate Number 115189. Recertified May 2000 for 2000-2010. Recertified October 2009 for 2010-2020.

Honors and Awards

- Phi Beta Kappa
- Alpha Omega Alpha
- Dean's Excellence Award, University of Texas Medical School-Houston, 1996
- Outstanding Achievement in Clinical Service, University of Texas Medical School-Houston, 1996
- Fellow, American College of Physicians (ACP), 1997
- 1999 Quality Team of the Year for Financial Improvement, Memorial Hermann Health Care System
- Memorial Hermann Hospital Physician of the Year, 2001
- Best Doctors in America, Infectious Diseases, 2002–04
- Excellence in Standards Development, Clinical & Laboratory Standards Institute, 2006
- Fellow, Infectious Diseases Society of America (IDSA), 2006
- Fellow, European College of Medical Mycology, 2016
- Fellow, Faculty of Pharmaceutical Medicine (FPM), Honorary, 2024

Professional Organizations:

- Infectious Diseases Society of America
- American Society for Microbiology
- International Society for Human and Animal Mycology
- American College of Physicians

FELLOWS TRAINED

David M. Cohen, M.D. (1992-1995), Marcelo Martins, M.D. (1993-1997), Monica Graziutti, M.D. (1994-1997), Libsen Rodriguez, M.D. (1995-1998), Mario Lozano-Chiu, Ph.D. (1995-1999), Sevta Arikian, MD. (1997-1998), Liang Xia, MD (1998-2000), Luis Ostrosky-Zeicher, MD (1999-2002), Banu Sancak, MD (2000-2001), Niki Paphitou, MD (2000-2002), Madonna Matar, MD (2001-2002), Roberto Andrade, MD (2001-2002),

PUBLICATIONS

Summary: Original Articles (129); Reviews, Editorials, and Invited Papers (54); Consensus Development, Guideline, and Policy Papers (42); Group Authorship (3); Book Chapters (63); Abstracts (151); Major Presentations at National and International Meetings (169)

A. Original Articles (in red when journal impact factor is 10+)

- Rex JH, Harris RL, Wheeler T, White M, Bradshaw M, Williams TW. Granulomatous disease complicating hairy cell leukemia. *Tex Med* 81:31-3, 1985.
- Harris RL, Lawrie GM, Wheeler TM, Rex JH, Sarosi GA, Jacob MC, Bradshaw MW, Williams TW. Successful management of *Histoplasma capsulatum* infection of an abdominal aortic aneurysm. *J Vasc Surg* 3:649-51, 1986.
- Rex JH, Ginsberg AM, Fries LF, Pass HI, Kwon-Chung KJ. *Cunninghamella bertholletiae* infection associated with deferoxamine therapy: A case report and review of the literature. *Rev Infect Dis* 10:1187-94, 1988.
- Rex JH, Bennett JE, Gallin JI, Malech HL, Melnick DA. Normal and deficient neutrophils can cooperate to damage *Aspergillus fumigatus* hyphae. *J Infect Dis* 162:523-528, 1990.
- Rex JH, Bennett JE. Administration of potassium iodide to normal volunteers does not increase killing of *Sporothrix schenckii* by their neutrophils or monocytes. *J Med Vet Mycol* 28:185-9, 1990.
- Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage *Aspergillus* hyphae. *J Infect Dis* 163:849-52, 1991.
- Rex JH, Hanson LH, Amantea MA, Stevens DA, Bennett JE. Standardization of a fluconazole bioassay and correlation with results obtained by high-pressure liquid chromatography. *Antimicrob Agents Chemother* 35:846-50, 1991.
- Kosinski RM, Axelrod P, Rex JH, Burday M, Sivaprasad R, Wreiole A. *Sporothrix schenckii* fungemia without disseminated sporotrichosis. *J Clin Microbiol* 30:501-503, 1992.
- Rex JH. Itraconazole-Digoxin Interaction [letter]. *Ann Int Med* 116:526, 1992.
- Geber A, Williamson PR, Rex JH, Sweeney EC, Bennett JE. Cloning and characterization of a *Candida albicans* maltase gene involved in sucrose utilization. *J Bacteriol* 174:6992-6, 1992.
- Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE. Catastrophic visual loss due to *Cryptococcus neoformans* meningitis. *Medicine* 72:207-224, 1993.
- Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. *J Clin Microbiol* 32:1650-1653, 1994.
- Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against *Candida species*. *J Infect Dis* 170:384-389, 1994.
- Okhuysen PC, Fife C, Kapusta M, Rex JH. Successful treatment of extensive soft tissue and renal *Apophysomyces elegans* infection in a normal host. *Clin Infect Dis* 19:329-331, 1994.
- Pfaller MA, Buschelman B, Lancaster M, Rinaldi M, Espinel-Ingroff A, Rex JH. Multicenter comparison of a colorimetric microbroth dilution method with the reference macrobroth dilution methods for in vitro susceptibility testing of yeast isolates. *Diag Microbiol Infect Dis* 19:9-13, 1994.
- Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Neu HC, Stern JJ, Tuazon CA, Dine AP, Levenstein MJ, Webb CD, the NIAID Mycoses Study Group, and the Candidemia Study Group. Fluconazole vs. amphotericin B for treatment of non-neutropenic patients with candidemia: Results of a randomized, multicenter trial. *N Engl J Med* 331:1325-1330, 1994. (Impact factor: 51.65)

Commented [JHR16]: Awards to Fellows-in-Training

1993: David Cohen received an honorable mention in the Annual M. D. Anderson Research Fellow Paper Competition
 1994: Marcelo Martins received first place in the annual Texas Infectious Diseases Society Research Fellow Paper Competition
 1995: Mario Lozano-Chiu received a Postdoctoral Research Award from the Sociedad Española de Quimioterapia to support his travel and first year of research
 1996: Mario Lozano-Chiu received an award from the Ministerio de Educación y Ciencia de España to support his travel and second year of research
 2000: Luis Ostrosky-Zeichner received a George McCracken ID Fellow Travel Grant for the 40th ICAAC in Toronto, Ontario
 2001: Luis Ostrosky-Zeichner received a George McCracken ID Fellow Travel Grant for the 41st ICAAC in Chicago, Illinois
 2001: Niki Paphitou received a George McCracken ID Fellow Travel Grant for the 41st ICAAC in Chicago, Illinois
 2002: Roberto Andrade received a George McCracken ID Fellow Travel Grant for the 42nd ICAAC in San Diego, CA
 2002: Niki Paphitou received a George McCracken ID Fellow Travel Grant for the 42nd ICAAC in San Diego, CA
 2002: Madonna Matar received a George McCracken ID Fellow Travel Grant for the 42nd ICAAC in San Diego, CA

Commented [Rex17]: Be sure to update LinkedIn as well when the totals change.

17. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD, the NIAID Mycoses Study Group, and the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole vs. amphotericin B as treatment of non-neutropenic patients with candidemia. *Antimicrob Agents Chemother* 39:40-44, 1995.
18. Rex JH, Cooper CR, Merz, WG, Anaissie EJ. Detection of amphotericin B-resistant *Candida* species in a broth-based system. *Antimicrob Agents Chemother* 39:906-909, 1995.
19. Rex JH, Bennett JE, Sugar AM. Treatment of candidemia [letter]. *N Engl J Med*. 332:1101-1102, 1995. (Impact factor: 51.65)
20. Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG, Cooper CR, McGinnis MR. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and 5-fluorocytosine. *J Clin Microbiol* 33:1104-1107, 1995.
21. Rex JH, Bhalla SC, Cohen DM, Hester JP, Vartivarian SE, Anaissie EJ. Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon- γ and granulocyte colony-stimulating factor. *Transfusion* 35:605-611, 1995.
22. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, Washburn RG, the NIAID Mycoses Study Group, and the Candidemia Study Group. Intravascular catheter exchanges and the duration of candidemia. *Clin Infect Dis* 21:994-996, 1995.
23. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards Broth Macrodilution Method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant *Candida* isolates. *Antimicrob Agents Chemother* 39:2520-2522, 1995.
24. Pfaller MA, Rhine-Chalberg J, Barry AL, Rex JH, the NIAID Mycoses Study Group, and the Candidemia Study Group. Strain variation and antifungal susceptibility among blood stream isolates of *Candida* species from 21 different medical institutions. *Clin Infect Dis* 21:1507-1509, 1995.
25. Vanek NN, Kazi S, Cepero NM, Tang S, Rex JH. Human ehrlichiosis causing left ventricular dilatation and dysfunction. *Clin Infect Dis* 22:386-387, 1996.
26. Rex JH, Pfaller MA, Lancaster M, Odds FC, Bolmström A, Rinaldi MG. Quality control Guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of ketoconazole and itraconazole. *J Clin Microbiol* 34:816-817, 1996.
27. Anaissie EJ, Paetznick VL, Ensign LG, Espinel-Ingroff A, Galgiani JN, Hitchcock CA, LaRocco M, Patterson T, Pfaller MA, Rex JH, Rinaldi MG. Microbroth antifungal susceptibility testing of *Candida albicans* and *Cryptococcus neoformans* with and without agitation: An eight-center collaborative study. *Antimicrob Agents Chemother* 40:2387-2391, 1996.
28. Pfaller MA, Messer SA, Bolmström A, Odds FC, Rex JH. Multisite reproducibility of the Etest agar diffusion MIC method for antifungal susceptibility testing of yeast isolates. *J Clin Microbiol* 34:1691-1693, 1996.
29. Espinel-Ingroff A, Bartlett M, Bowden R, Chin NX, Cooper C, Jr., Fothergill A, McGinnis MR, Menezes P, Messer SA, Nelson PW, Odds FC, Pasarell L, Peter J, Pfaller MA, Rex JH, Rinaldi MG, Shankland J, Walsh TJ, Weitzman I. Multicenter evaluation of standardization of antifungal susceptibility testing for filamentous fungi. *J Clin Microbiol* 35:139-143, 1997.
30. Lozano-Chiu M, Nelson PW, Lancaster M, Pfaller MA, Rex JH. Lot-to-lot variability of Antibiotic Medium 3 when used for susceptibility testing of *Candida* to amphotericin B. *J Clin Microbiol* 35:270-272, 1997.
31. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL, for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of *in vitro-in vivo* correlation data for fluconazole, itraconazole, and *Candida* infections. *Clin Infect Dis* 24:235-247, 1997.
32. Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets [letter]. *Ann Int Med* 126:332-333, 1997.
33. Cohen DM, Bhalla SC, Anaissie EJ, Hester JP, Savary CA, Rex JH. Effects of *in vitro* and *in vivo* cytokine treatment, leucapheresis, and irradiation on the function of human neutrophils: Implications for white blood cell transfusion therapy. *Clin Lab Haematol* 19:39-47, 1997.

34. Nelson PW, Chiu ML, Rex JH. *In vitro* growth inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant *Candida* isolates: Influence of assay conditions. *J Med Vet Mycol* 35:285-287, 1997.
35. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of symptomatic and asymptomatic carriage of fluconazole-resistant *Candida* in the oropharynx of HIV-infected patients. *Clin Infect Dis* 25:843-846, 1997.
36. Wallace TL, Paetznick V, Cossum PA, Lopez-Berenstein G, Rex JH, Anaissie EJ. Activity of liposomal nystatin against disseminated *Aspergillus fumigatus* in neutropenic mice. *Antimicrob Agents Chemother* 41:2238-2243, 1997.
37. Graziutti ML, Rex JH, Cowart RE, Anaissie EJ, Ford A, Savary CA. *Aspergillus fumigatus* conidia induce a Th1-type cytokine response. *J Infect Dis* 176:1579-1583, 1997.
38. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Andersson BS, Freireich EJ. Treatment of neutropenia-related fungal infections with granulocyte-colony stimulating factor-elicited white blood cell transfusions: A pilot study. *Leukemia* 11:1621-1630, 1997. (Impact factor 10.164)
39. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing *in vitro* and therapeutic outcome *in vivo* for fluconazole by testing critical isolates in a murine model of invasive candidiasis. *Antimicrob Agents Chemother* 42:129-134, 1998.
40. Savary CA, Graziutti ML, Melichar B, Przepiorka D, Freedman RS, Cowart RE, Cohen DM, Anaissie EJ, Woodside DG, McIntyre BW, Pierson DL, Pellis NR, Rex JH. Multidimensional flow cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. *Cancer Immunology and Immunotherapy* 45:234-240, 1998.
41. Anaissie EJ, Rex JH, Uzun Ö, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. *Am J Med* 104:238-245, 1998.
42. Odds FC, van Gerven F, Espinel-Ingroff A, Bartlett MS, Ghannoum MA, Lancaster MV, Pfaller MA, Rex JH, Rinaldi MG, Walsh TJ. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi *in vitro* and antifungal treatment outcomes in animal infection models. *Antimicrob Agents Chemother* 42:282-288, 1998.
43. Lozano-Chiu M, Lancaster MV, Rex JH. Evaluation of a colorimetric method for detecting amphotericin B-resistant *Candida* isolates. *Diagnostic Micro and Infect Dis* 31:417-424, 1998.
44. Martins MD, Rodriguez LJ, Savary CA, Graziutti ML, Deshpande D, Cohen DM, Cowart RE, Woodside DG, McIntyre B, Anaissie EJ, Rex JH. Activated lymphocytes reduce adherence of *Aspergillus fumigatus*. *Medical Mycology* 36:281-289, 1998.
45. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of symptomatic oropharyngeal candidiasis, carriage of *Candida albicans*, and fluconazole resistance in HIV-infected patients. *Clin Infect Dis* 27:1291-1294, 1998.
46. Lozano-Chiu, M, Paetznick V, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among *Cryptococcus neoformans* clinical isolates: Performance of three different media using Etest and the National Committee for Clinical Laboratory Standards M27-A methodologies. *J Clin Microbiol* 36:2817-2822, 1998.
47. Pfaller MA, Arikan S, Lozano-Chiu M, Chen Y-S, Coffman S, Messer SA, Rennie R, Sand C, Heffner T, Rex JH, Wang J, Yamane N. Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing. *J Clin Microbiol* 36:2609-2612, 1998.
48. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. *Antimicrob Agents Chemother* 43:589-591, 1999.
49. Lozano-Chiu M, Nelson PW, Paetznick VL, Rex JH. A Disk diffusion method for determining the susceptibility of *Candida* spp. to MK-0991. *J Clin Microbiol* 37:1625-1627, 1999.
50. Marr KA, Rustand TR, Rex JH, White TC. The trailing endpoint phenotype in antifungal susceptibility testing is pH-dependent. *Antimicrob Agents Chemother* 43:1383-1386, 1999.
51. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Rex JH. Optimizing voriconazole susceptibility testing of *Candida*: Effects of incubation time, endpoint rule, species of *Candida*, and level of fluconazole susceptibility. *J Clin Microbiol* 37:2755-2759, 1999.
52. Arikan S, Lozano-Chiu M, Paetznick V, Nangia A, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of *Aspergillus* and *Fusarium* species. *J Clin Microbiol* 37:3946-3951, 1999.
53. Rex JH, Turnbull JE, Allen SJ, Vande Voorde K, Luther K. Systematic root cause analysis of adverse drug events in a tertiary referral hospital. *Jt Comm J Qual Improv* 26:563-575, 2000.

54. Barry AL, Pfaller MA, Brown SD, Espinel-Ingroff A, Ghannoum MA, Knapp C, Rennie RP, Rex JH, Rinaldi MG. Quality control limits for broth microbiology susceptibility tests of ten antifungal agents. *J Clin Microbiol* 38:3457-3459, 2000.
55. Arikian S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against *Aspergillus* and *Fusarium* isolates. *Antimicrob Agents Chemother* 45:327-30, 2001.
56. Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, Carillo-Munoz AJ, Chavanet P, Cloud GA, Denning DW, de Pauw BE, Edwards, Jr. JE, Hiemenz JW, Kauffman CA, Lopez-Berestein G, Martino P, Sobel JD, Stevens DA, Sylvester R, Tollemar J, Viviani MA, Viscoli C, Wu T. Alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. *Clin Infect Dis* 33:95-106, 2001.
57. Uzun O, Ascioğlu, S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in cancer patients with breakthrough candidemia. *Clin Infect Dis* 32:1713-1717, 2001.
58. Graziuiti M, Przepiorka D, Rex JH, Braunschweig I, Vadhan-Raj S, Savary CA. Dendritic cell-mediated stimulation of lymphocytic response to *Aspergillus fumigatus* in stem cell transplant recipients and normal volunteers. *Bone Marrow Transplant* 27:647-52, 2001.
59. Savary CA, Graziuiti ML, Przepiorka D, Tomasovic SP, McIntyre BW, Woodside DG, Pellis NR, Pierson DL, and Rex JH. Effects of simulated microgravity on human dendritic cells. *In Vitro Cell Dev Biol Anim* 37:216-2, 2001
60. Anaissie, EJ, Kuchar, R, Rex JH, Francesconi A, Kasai, M, Müller FM, Lozano-Chiu, M, Summerbell R, Chanock S, Walsh T. Pathogenic *Fusarium* Species in a Hospital Water System: Implications for transmission of opportunistic mycoses in immunocompromised patients. *Clin Infect Dis* 33:1871-8, 2001.
61. Ostrosky-Zeichner L, Bazemore S, Cossup P, Paetznick VL, Rodriguez JR, Chen E, Wallace T, and Rex JH. Differential antifungal activity of isomeric forms of nystatin. *Antimicrob Agents Chemother* 45:2781-2786, 2001.
62. Ascioğlu S, Rex JH, De Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer: An international consensus. *Clin Infect Dis* 34:7-14, 2002.
63. Arikian S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against *Aspergillus* and *Fusarium* spp. *Antimicrob Agents Chemother* 46:245-7, 2002.
64. Anaissie EJ, Stratton SL, Dignani MC, Summerbell RC, Rex JH, Monson TP, Spencer T, Kasai M, Francesconi A, Walsh TJ. Pathogenic *Aspergillus* species recovered from a hospital water system: A 3-year prospective study. *Clin Infect Dis* 34:780-789, 2002
65. Arikian S, Ostrosky-Zeichner L, Lozano-Chiu M, Paetznick V, Gordon D, Wallace T, Rex JH. In vitro activity of nystatin compared with liposomal nystatin, amphotericin B, and fluconazole against clinical *Candida* isolates. *J Clin Microbiol* 40:1406-1412, 2002.
66. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of *Trichosporon* species. *Antimicrob Agents Chemother* 2002;46:1144-1146, 2002.
67. Rex JH, Anaissie EJ, Boutati E, Estey E, Kantarjian H. Systemic antifungal prophylaxis reduces invasive fungal infections in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults *Leukemia* 16:1197-1199, 2002. (Impact factor 10.164)
68. Ripeau JS, Aumont F, Belhumeur P, Ostrosky-Zeichner L, Rex JH, de Repentigny L. Effect of the echinocandin caspofungin on expression of *Candida albicans* secretory aspartyl proteinases and phospholipase in vitro. *Antimicrob Agents Chemother* 46:3096-100, 2002.
69. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, and Rex JH. In vitro activity of investigational triazoles against *Fusarium* species: Effects of inoculum size and incubation time on broth microdilution susceptibility test results. *Antimicrob Agents Chemother* 46:3298, 2002.
70. Arikian S, Paetznick V, Rex JH. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against *Aspergillus* and *Fusarium*. *Antimicrob Agents Chemother* 46:3084–3087, 2002.
71. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Rex JH, Summerbell RC, Walsh TJ. Cleaning patient shower facilities: A novel approach to reducing patient exposure to aerosolized *Aspergillus* species and other opportunistic molds. *Clin Infect Dis* 35:e86–8, 2002.
72. Sancak B, Rex JH, Paetznick V, Chen E, Rodriguez J. Identification of *Candida dubliniensis* in the Clinical Laboratory: A Comparison Of Methods. *J Clin Microbiol* 41:489-491, 2003.

73. Anaissie EJ, Stratton SL, Dignani MC, Lee C-K, Summerbell RC, Rex JH, Monson TP, Walsh TJ. Pathogenic moulds (including *Aspergillus* spp.) in hospital water distribution systems: A three-year prospective study and clinical implications for patients with hematological malignancies. *Blood* 101:2542-2546, 2003.
74. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. *Clin Infect Dis* 36:1221-8, 2003.
75. Rodríguez-Adrián LJ, King RT, Tamayo T, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, etiology. *Medicine* 82:187-202, 2003.
76. Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, Donnelly JP, Dromer F, Dupont B, Rex JH, Richardson MD, Sancak B, Verweij PE, Rodríguez-Tudela JL, and The AFST Subcommittee of European Committee on Antibiotic Susceptibility Testing. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method of EUCAST. *Clin Microbiol Infect* 9:467-74, 2003.
77. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodríguez JR, Chen E, and Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. *Antimicrob Agents Chemother* 2003;47:1647-1651.
78. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, and the NIAID Mycoses Study Group. A prospective observational study of candidemia: Epidemiology, therapy and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis* 37:634-643, 2003.
79. Odabasi Z, Paetznick V, Goldstein BP, Rex JH, Ostrosky-Zeichner L. Disk diffusion-based methodologies for determining susceptibility of *C. parapsilosis* to anidulafungin. *Antimicrob Agents Chemother* 47:3018-3020, 2003.
80. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HG, Powderly WG, Hyslop N, Kaufman CA, Chapman SW, Mangino JE, Lee J, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group Candidiasis Subproject. Comparative antifungal susceptibility survey of 2,000 bloodstream isolates of *Candida* spp. from the United States. *Antimicrob Agents Chemother* 47:3149-54, 2003.
81. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. *Eur J Clin Microbiol Infect Dis* 22:651-5, 2003.
82. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial Gram-negative infections in critically ill patients. *Diagn Microbiol Infect Dis* 48:125-30, 2004.
83. Chaturvedi V, Ramani R, Rex JH. A collaborative study of Antibiotic Medium 3 and flow cytometry for identification of amphotericin B-resistant *Candida* isolates. *J Clin Microbiol* 42:2252-2254, 2004.
84. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cut-off development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin Infect Dis* 39:199-205, 2004.
85. Mohr JF, Finkel KW, Rex JH, Rodríguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacokinetics of intravenous itraconazole dosed before and after dialysis in stable hemodialysis patients. *Antimicrob Agents Chemother* 48:3151-3, 2004.
86. Odds FC, Motyl M, Andrade R, Bille J, Canton E, Cuenca-Estrella M, Davidson A, Durussel C, Ellis D, Foraker E, Fothergill AW, Ghannoum MA, Giacobbe RA, Gobernado M, Handke R, Laverdiere M, Lee-Yang W, Merz WG, Ostrosky-Zeichner L, Peman J, Perea S, Perfect JR, Pfaller MA, Proia L, Rex JH, Rinaldi MG, Rodríguez-Tudela JL, Schell WA, Shields C, Sutton DA, Verweij PE, Warnock DW. Interlaboratory comparison of results of susceptibility testing with caspofungin against *Candida* and *Aspergillus* species. *J. Clin. Microbiol.* 42 3475-3482, 2004.
87. Sancak B, Rex JH, Chen E, Marr K. Comparison of PCR- and *HinfI* restriction endonuclease-based methods for typing of *Candida krusei* isolates. *J Clin Microbiol* 42:4889-5891, 2004.
88. Dignani MC, Rex JH, Chan K-W, Dow G, de Magalhaes-Silverman M, Maddox AM, Walsh T, Anaissie E. Immunomodulation with interferon- γ and colony stimulating factors as salvage therapy for refractory invasive fungal infections in immunocompromised patients. *Cancer* 104:199-204, 2005.

89. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1 -> 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis* 2005;41:654-659.
90. Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against *Aspergillus* spp. and *Fusarium* spp. *Antimicrob Agents Chemother* 2005;49:3572-3574.
91. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Preston Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. A randomized, prospective, multicenter study of voriconazole versus a regimen of amphotericin B followed by fluconazole in the treatment of candidemia in nonneutropenic patients. *Lancet* 366:1435-42, 2005. (Impact factor 30.06)
92. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. *Eur J Clin Microbiol Infect Dis* 24:654-61, 2005.
93. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. *Med Mycol* 43:235-43, 2005.
94. Philip A, Odabasi Z, Matiuizzi G, Paetznick VL, Tan SW, Warmington J, Rex JH, Ostrosky-Zeichner L. Syscan3, a kit for detection of anti-*Candida* antibodies for diagnosis of invasive candidiasis. *J Clin Microbiol.* 43:4834-5, 2005
95. Kullberg BJ, Rex JH, Ruhnke M, Sobel JD, Pappas PG. Candidemia secondary to intravascular catheter colonisation? *Lancet* 367:728-9, 2006. (Impact factor 30.06)
96. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, Chaturvedi V, Ghannoum MA, Odds FC, Rinaldi MG, Sheehan DJ, Troke P, Walsh TJ, Warnock DW. Correlation of MIC with outcome for *Candida* species tested against voriconazole: analysis and proposal for interpretive breakpoints. *J Clin Microbiol* 44:819-26, 2006.
97. Pfaller MA, Diekema DJ, Rex JH. Does one voriconazole breakpoint suit all *Candida* species? Reply. *J Clin Microbiol* 2007;45:2094.
98. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. *Eur J Clin Micro Infect Dis*, 26:271-276, 2007.
99. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L. Effects of serum on in vitro susceptibility testing of the echinocandins. *Antimicrob Agents Chemother.* 51:4214-6, 2007
100. Chaturvedi V, Ramani R, Ghannoum MA, Killian SB, Holliday N, C Knapp, Ostrosky-Zeichner L, Messer SA, Pfaller MA, Iqbal NJ, Arthington-Skaggs BA, Vazquez JA, Sein T, Rex JH, Walsh TJ. Multilaboratory testing of antifungal combinations against a quality control isolate of *Candida krusei*. *Antimicrob Agents Chemother.* 52: 1500-1502, 2008.
101. Schuster MG, Edwards JE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Swanson RN, Panzer H, Rex, JH. Empiric fluconazole versus placebo for intensive care unit patients: A randomized trial. *Ann Intern Med* 149:83-90, 2008. (Impact factor 13.976)
102. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Correlation of MIC with Outcome for *Candida* species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. *J Clin Microbiol* 46:2620-9, 2008.
103. Ostrosky-Zeichner L, Rex JH, Pfaller MA, Diekema DJ, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Rationale for reading fluconazole MICs at 24h rather than 48h when testing *Candida* spp. by the CLSI M27-A2 standard method. *Antimicrob Agents Chemother.* 52:4175-7, 2008.
104. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl1MR, Ostrosky-Zeichner LO, Sheehan DJ, Walsh TJ. Wild type MIC distribution and epidemiological cutoff values for *Aspergillus fumigatus* and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. *J Clin Microbiol* 47:3142-3146, 2009.

105. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Rex JH, Leitz GJ, Ostrosky-Zeichner L. Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. *Mycoses* 53:438-42, 2010
106. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, Ostrosky-Zeichner L. A Prospective Survey of (1→3)-β-D-glucan and its Relationship to Invasive Candidiasis in the Surgical ICU Setting. *J Clin Microbiol* 49:58-61, 2010.
107. Oude-Lashof AML, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ. Ocular Manifestations of Candidemia. *Clin Infect Dis* 53:262–268, 2011.
108. Spellberg B, Sharma P, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. *Nature Rev Drug Disc* 11:168-70, 2012. (Impact Factor 33.078)
109. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. *Clin Infect Dis* 54:1110-22, 2012.
110. Oude Lashof AML, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Rex JH, Kullberg BJ. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. *Antimicrob Ag Chemother* 56:3133-7, 2012.
111. Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Fuller J, Ghannoum M, Jones RN, Lockhart SR, Martin-Mazuelos E, Melhem MSC, Ostrosky-Zeichner L, Pappas P, Pelaez T, Peman J, Rex JH, Szeszs MS. Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and *Candida* spp. as Determined by CLSI Broth Microdilution. *J Clin Microbiol* 50:2040-6, 2012.
112. Spellberg B, Rex JH. The value of single-pathogen antibacterial agents. *Nature Rev Drug Disc* 12:963-963, 2013. (Impact Factor 33.078)
113. Rex JH, Outterson, K. Antibiotic Reimbursement in a Sales-Delinked Model: Context and a Benchmark-Based Global Approach. *The Lancet Infectious Diseases* 16:500-505, 2016. (Impact factor 19.97)
114. Biswas C, Law D, Birch M, Halliday C, Sorrell TC, Rex J, Slavin M, and Chen SCA. In vitro activity of the novel antifungal compound F901318 against Australian *Scedosporium* and *Lomentospora* fungi. *Med Mycol*, <https://doi.org/10.1093/mmy/myx161>, 2018.
115. Wiederhold N, Najvar L, Jaramillo R, Olivo M, Birch M, Law D, Rex J, Catano G, and Patterson T. The Orotomide Olorofim is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. *Antimicrob Ag Chemother* 62(9): pii: e00999-18. doi: 10.1128/AAC.00999-18., 2018.
116. Theuretzbacher U, Gottwalt S, Beyer P, Butler, M, Czapplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spiegelman M, Thwaites G, Paccaud JP, Harbarth S. WHO's analysis of the clinical antibacterial and antituberculosis pipeline *The Lancet Infectious Diseases* 19(2): pii: S1473-3099(18)30513-9. doi: 10.1016/S1473-3099(18)30513-9, 2018. (Impact factor 19.97).
117. Seyedmousavi S, Chang Y, Law D, Birch M, Rex JH, and Kwon-Chung K. Efficacy of olorofim (F901318) against *Aspergillus fumigatus*, *A. nidulans*, and *A. tanneri* in murine models of profound neutropenia and chronic granulomatous disease. *Antimicrob Ag Chemother* 63:e00129-19, 2019.
118. Bader JC, Lakota EA, Dale GE, Sader HS, Rex JH, Ambrose PG, et al. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. *Antimicrobial Agents and Chemotherapy*. 63:e00318-19, 2019.
119. Theuretzbacher U, Bush B, Harbarth S, Paul M, Rex J, Thwaites G, Tacconelli E. Critical analysis of antibacterial agents in clinical development. *Nat Rev Microbiol* 18(5):286-298, 2020 (Impact Factor 32.851).
120. Outterson K, Rex JH. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. *Translational Research*, DOI: <https://doi.org/10.1016/j.trsl.2020.02.006>, 2020.
121. Outterson K, Orubu ESF, Rex JH, Ardal C, Zaman MH, Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020. *Clin Infect Dis*. 2021 Jul 12;ciab612. doi: 10.1093/cid/ciab612.
122. Colson AR, Morton A, Ardal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, Woods B, Xiao Y. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? *Value in Health*, Volume 24, Issue 12, 1828 - 1834, 2021.

123. Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. *Antimicrob Agents Chemother*. 2022 Mar 15;66(3):e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10. PMID: 35007139; PMCID: PMC8923189.
124. Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P. Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant *Enterobacteriales* Are Critical Priority Pathogens, Too!". *Antimicrob Agents Chemother*. 2022 Apr 19;66(4):e0022322. doi: 10.1128/aac.00223-22. Epub 2022 Mar 24. PMID: 35323014; PMCID: PMC9017292.
125. Seyedmousavi S, Chang YC, Youn JH, Law D, Birch M, Rex JH, Kwon-Chung KJ. In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis. *Antimicrob Agents Chemother*. 2021 Sep 17;65(10):e0043421. doi: 10.1128/AAC.00434-21. Epub 2021 Jul 12. PMID: 34252298; PMCID: PMC8448127.
126. Dane A, Rex JH, Newell P, Stallard N: The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens. *Open Forum Infectious Diseases* 2022, <https://doi.org/10.1093/ofid/ofac266>.
127. Yasinskaya Y, Bala S, Waack U, Dixon C, Higgins K, Moore JN, Jjingo CJ, O'Shaughnessy E, Colangelo P, Botgros R, Nambiar S, Angulo D, Dane A, Chiller T, Hodges MR, Sandison T, Hope W, Walsh TJ, Pappas P, Katragkou A, Kovanda L, Rex JH, Marr KA, Ostrosky-Zeichner L, Sekine S, Deshpande M, Shukla SJ, Farley J. Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need. *Clin Infect Dis*. 2023 Aug 14;77(3):380-387. doi: 10.1093/cid/ciad195.
128. Outterson K, Rex JH. Global Pull Incentives for Better Antibacterials: The UK Leads the Way. *Appl Health Econ Health Policy*. 2023 May;21(3):361-364. doi: 10.1007/s40258-023-00793-w. Epub 2023 Feb 11. PMID: 36773115; PMCID: PMC10119039
129. Gigante V, Alm RA, Melchiorri D, Rocke T, Arias CA, Czaplewski L, Fernandes P, Franceschi F, Harbarth S, Kozlov R, Lienhardt C, Ohmagari N, Ogilvie LA, Paul M, Rex JH, Silver LL, Spigelman M, Sati H, Cameron AM. Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps. *Antimicrob Agents Chemother*. 2024 Aug 7;68(8):e0053524. doi: 10.1128/aac.00535-24. Epub 2024 Jul 15. PMID: 39007560; PMCID: PMC11304740.

Commented [JR18]: Update counts above

B. Reviews, Editorials, and Invited Papers

1. Rex JH. Recent advances in the immunodiagnosis of disseminated candidiasis and histoplasmosis. *Resident & Staff Physician*, October Supplement:7-12, 1991.
2. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. *Clin Microbiol Rev* 5:367-381, 1993.
3. Rex JH, Rinaldi MG, Pfaller MA. Resistance of *Candida* species to fluconazole. *Antimicrob Agents Chemother* 39:1-8, 1995.
4. Rodriguez LJ, Rex JH, Anaissie EJ. Update on invasive candidiasis. *Advan Pharmacol* 37:349-400, 1996.
5. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: Current status of the correlation of in vitro data with clinical outcome. *J Clin Microbiol* 34:489-495, 1996.
6. Rex JH. Catheters and candidemia [editorial]. *Clin Infect Dis* 22:467-470, 1996.
7. Martins MD, Rex JH. Resistance to antifungal agents in the critical care setting: Problems and perspectives. *New Horizons* 4:338-344, 1996.
8. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: Technical advances and potential clinical applications. *Clin Infect Dis* 24:776-84, 1997.
9. Rex JH, Walsh TJ, Anaissie EJ. Fungal Infections in iatrogenically compromised hosts. *Adv Intern Med* 43:321-371, 1997.
10. Rodriguez-Adrian LJ, Graziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed? *Clin Infect Dis* 26:1270-1278, 1998.
11. Vanden Bossche H, Dromer F, Improvisi L, Lozano-Chiu M, Rex JH, Sanglard, D. Antifungal drug resistance in pathogenic fungi. *Med Mycol* 36 (Suppl. 1):119-128, 1998.
12. Coleman DC, Rinaldi MG, Haynes KA, Rex JH, Summerbell RC, Anaissie, EJ, Li A, Rex JH, Sullivan DJ. Importance of *Candida* species other than *Candida albicans* as opportunistic pathogens. *Med Mycol* 36 (Suppl. 1):156-165, 1998.
13. Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. *Med Mycol* 36 (Suppl. 1):12-25, 1998.

14. Rex JH, Sobel JD. Preventing intraabdominal candidiasis in surgical patients. *Crit Care Med* 27:1033-4, 1999.
15. Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. *Clin Infect Dis* 29:1408-10, 1999.
16. Arikan S, Rex JH. New agents for treatment of systemic fungal infections. *Emerging Drugs* 5:135-160, 2000.
17. Arikan S, Rex JH. NS-718: A novel formulation of amphotericin B. *Curr Opin Investig Drugs* 2:413-415, 2000.
18. Clemons KV, Calich VLG, Burger E, Filler SG, Graziutti M, Murphy J, Roilides E, Campa A, Dias MR, Edwards JE, Fu Y, Fernandes-Bordignon G, Ibrahim A, Katsifa H, Lamaignere CG, Meloni-Bruner LH, Rex J, Savary CA, Xidieh C. Pathogenesis I: Interactions of host cells and fungi. *Med Mycol* 38 (Suppl. 1), 99-111, 2000.
19. Tiraboschi IN, Bennett JE, Kauffman CA, Rex JH, Girmenia C, Sobel JD, Menichetti F. Deep *Candida* infections in the neutropenic and non-neutropenic host: an ISHAM symposium. *Med Mycol* 38 (Suppl. 1), 199-204, 2000.
20. Dupont B, Crewe-Brown HH, Westermann K, Martins MD, Rex JH, Lortholary O, Kauffman CA. Mycoses in AIDS. *Med Mycol* 38 (Suppl. 1), 259-267, 2000.
21. Arikan S, Rex JH. Lipid-based antifungal agents: current status. *Curr Pharm Des* 7:393-415, 2001.
22. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. *Clin Infect Dis* 32:1191-200, 2001.
23. Sobel JD, Rex JH. Invasive candidiasis: Turning risk into a practical prevention policy? *Clin Infect Dis* 33:187-190, 2001.
24. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FD, Rinaldi MG, Sheehan DJ, Warnock DJ. Antifungal Susceptibility Testing: Practical aspects and current challenges. *Clin Microbiol Rev* 14:643-658, 2001.
25. Arikan S, Rex JH. Nystatin LF. *Curr Opin Investig Drugs* 2:488-495, 2001.
26. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: Assessment of the balance between the risks and benefits of removal of vascular catheters. *Clin Infect Dis* 34:600-602, 2002.
27. Ostrosky-Zeichner L, Rex JH, Bennett JE, Kullberg, B-J. Deeply invasive candidiasis. *Infectious Disease Clinics of North America* 16:821-835, 2002.
28. Arikan S, Rex JH. New agents for treatment of systemic fungal infections. *Emerging Drugs* 7:1-29, 2002.
29. Arikan S, Rex JH. Ravuconazole. *Curr Opin Investig Drugs* 3:555-561, 2002.
30. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? *Clin Infect Dis* 35:982-989, 2002.
31. Rex JH. Voriconazole: A viewpoint. *Drugs* 18:2665-2666, 2002.
32. Walsh TJ, Rex JH. Preface - Fungal infections, - Part I - Recent advances in diagnosis, treatment, and prevention of opportunistic mycoses. *Infect Dis Clin N Amer* 16:IX-X, 2002.
33. Walsh TJ, Rex JH. Fungal infections, Part II - Recent advances in diagnosis, treatment, and prevention of endemic and cutaneous mycoses - Preface. *Infect Dis Clin N Amer* 17:XI-XII, 2003.
34. Ostrosky-Zeichner LO, Marr KA, Rex JH, Cohen SH. Amphotericin B: Time for a New Gold Standard. *Clin Infect Dis* 37:415-425, 2003.
35. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activity against yeasts and moulds: Lessons to be learned from bactericidal testing and the need for standardization. *Clin Micro Rev* 17:268-280, 2004.
36. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. *Antimicrob Agents Chemother* 48:693-715, 2004.
37. Rex JH. *Staying ahead of the fourth horseman. Nature Rev Microbiol Rev* 2:684, 2004. (Impact Factor 22.49)
38. Rex JH, Wingard JR, Wenzel R, Herbrecht R, Sobel J, and Edwards JE. The design of clinical trials evaluating antifungal prophylaxis and combination therapy: Symposium introduction and overview. *Clin Infect Dis* S165-169, 2004.
39. Sims CR, Ostrosky-Zeichner L, Rex JH. Invasive candidiasis in immunocompromised hospitalized patients. *Arch Med Res* 36:660-71, 2005.
40. Rex JH. *Candida* in the peritoneum: Passenger or pathogen? *Crit Care Med* 34:902-3, 2006.
41. Rex JH. Antifungal prophylaxis in the ICU: Who should get it? *Crit Care Med* 34:1286-7, 2006.
42. Rex JH. Galactomannan and the diagnosis of invasive aspergillosis. *Clin Infect Dis* 42:1428-30, 2006.
43. Rex JH, Hayden FB. Anti-infectives: New trends, new approaches. *Curr Opin Pharmacol* 7:453-4, 2007.
44. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. *Nature Rev Microbiol* 9:719-27, 2010. (Impact Factor 33.078)
45. Rex JH. ND4BB: Addressing the antimicrobial resistance crisis. *Nature Rev Microbiol* 12:231-232 2014. (Impact Factor 33.078)
46. Czaplewski L, Bax E, Clokie M, Dawson M, Fairhead H, Fischetti VA, Gilmore BF, Hancock REW, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J,

- Thomas CM, Trust TJ, Warn P, Rex JH. Alternatives to antibiotics – a pipeline portfolio review. *The Lancet Infectious Diseases* (in press), 2016. (Impact factor 19.97)
47. Hope WW, Drusano G, Rex JH. Pharmacodynamics for Antifungal Drug Development: an Approach for Acceleration, Risk Minimisation and Demonstration of Causality. *J Antimicrob Chemother* 71(11):3008-3019, 2016.
 48. Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Accelerating global innovation to address antibacterial resistance: Introducing CARB-X. *The Lancet Infectious Diseases* doi:10.1038/nrd.2016.155. Published online 29 July 2016. (Impact factor 19.97)
 49. Rex JH, Talbot GH, Goldberger MJ, Eisenstein BI, Echols RM, Tomayko JF, Dudley MN, Dane A. Progress in the fight against multidrug-resistant bacteria 2005-2016: Modern non-inferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. *Clinical Infectious Diseases* 65:141-6, 2017.
 50. Bhavnani SM and Rex JH. Editorial overview: Use of PK-PD for antibacterial drug development: Decreasing risk and paths forward for resistant pathogens. *Curr Opin Pharmacol* 36:viii-xii, 2017.
 51. Rex JH, Fernandez Lynch H, Cohen IG, Darrow JJ, Outterson K. Designing development programs for non-traditional antibacterial agents. *Nature Communications*. 10(1):3416, 2019 (Impact factor 11.88).
 52. Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex J, and Sumpradit N. Antibiotic development – economic, regulatory and societal challenges. *Nat Rev Microbiol* 18, 267–274, 2020. (Impact Factor 33.078).
 53. Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. *Clin Infect Dis*. 2021 May 4;72(9):e420–e421. doi: 10.1093/cid/ciaa092. PMID: 31999818.
 54. Outterson K, Rex JH. Global Pull Incentives for Better Antibacterials: The UK Leads the Way. *Appl Health Econ Health Policy*. 2023 Feb 11. doi: 10.1007/s40258-023-00793-w. Epub ahead of print. PMID: 36773115.

Commented [Rex19]: If you add, adjust paper counts, above

C. Consensus Development, Guideline, and Policy Papers

1. Galgiani JN, Bartlett MS, Ghannoum MA, Espinel-Ingroff A, Lancaster MV, Odds FC, Pfaller MA, Rex JH, Rinaldi MG. Reference method for broth dilution antifungal susceptibility testing of yeasts: Tentative standard. NCCLS document M27-T. National Committee for Clinical Laboratory Standards, Villanova, PA, 1995.
2. Edwards JE, Jr., Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Roger TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M. International conference for the development of a consensus on the management and prevention of severe candidal infections. *Clin Infect Dis* 25:43-59, 1997.
3. Galgiani JN, Bartlett MS, Ghannoum MA, Espinel-Ingroff A, Lancaster MV, Odds FC, Pfaller MA, Rex JH, Rinaldi MG. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.
4. Pfaller MA, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Odds FC, Rex JH, Rinaldi MG, Walsh TJ. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard. NCCLS document M38-P. Wayne, Pa: National Committee for Clinical Laboratory Standards, 1998.
5. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE. Practice guidelines for treatment of candidiasis. *Clin Infect Dis* 30:662-78, 2000.
6. Pfaller MA, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rex JH, Rinaldi MG, Sheehan DJ, Walsh TJ, Warnock DW. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard—second edition. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
7. Pfaller MA, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rex JH, Rinaldi MG, Sheehan DJ, Walsh TJ, Warnock DW. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2002.
8. Sheehan DJ, Brown SD, Pfaller MA, Warnock DW, Rex JH, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Walsh TJ. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Proposed standard. NCCLS document M44-P. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2003.
9. Bennett JE, Powers J, Walsh T, Viscoli C, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, Lee J, Pappas P, Rex J, and Verweij P. Issues in clinical trials of empirical antifungal therapy in febrile neutropenic patients. *Clin Infect Dis* 36 (Suppl. 3): S117-122, 2003.

10. Bennett JE, Powers J, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, Lee J, Pappas P, Rex J, Verweij P, Viscoli C, and Walsh T. Issues in the design of drug trials for invasive aspergillosis. *Clin Infect Dis* 36 (Suppl. 3): S113-116, 2003.
11. Bennett JE, Kauffman C, Walsh T, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Lee J, Pappas P, Powers J, Rex J, Verweij P, Viscoli C. Issues in the evaluation of diagnostic tests, use of historical controls and the merits of the current multicenter collaborative groups. *Clin Infect Dis* 36 (Suppl. 3): S123-127, 2003.
12. Sheehan DJ, Brown SD, Pfaller MA, Warnock DW, Rex JH, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Walsh TJ. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Approved Guideline. NCCLS document M44-A. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2004.
13. Rex JH, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Odds FC, Pfaller MA, Rinaldi MG, Sheehan DJ, Steele-Moore L, Walsh TJ, Warnock DW. Quality Control MIC Limits for Broth Microdilution; Informational Supplement. NCCLS document M27-S1. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2004.
14. Pappas PG, Rex JH, Sobel JD, Walsh TJ, Filler SG, Dismukes WE, Edwards JE. Practice guidelines for treatment of candidiasis. *Clin Infect Dis* 38:161-189, 2004.
15. Rex JH, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Odds FC, Pfaller MA, Rinaldi MG, Sheehan DJ, Steele-Moore L, Walsh TJ, Warnock DW. Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints; Informational Supplement. NCCLS document M27-S2. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2005.
16. Rex JH, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Odds FC, Pfaller MA, Rinaldi MG, Sheehan DJ, Steele-Moore L, Walsh TJ, Warnock DW. Zone Diameter Interpretive Standards and Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints; Informational Supplement. NCCLS document M44-S1. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2005.
17. Rex JH, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Odds FC, Pfaller MA, Rinaldi MG, Sheehan DJ, Steele-Moore L, Walsh TJ, Warnock DW. Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution; Informational Supplement. NCCLS document M38-S1. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2005.
18. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturvedi V, Ghannoum MA, Espinel-Ingroff A, Knapp CC, Ostrosky-Zeichner L, Pfaller MA, Sheehan DJ, Walsh TJ. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition. CLSI document M27-A3 (ISBN 1-56238-666-2). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2008.
19. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturvedi V, Ghannoum MA, Espinel-Ingroff A, Knapp CC, Ostrosky-Zeichner L, Pfaller MA, Sheehan DJ, Walsh TJ. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. CLSI document M27-S3 (ISBN 1-56238-000-0). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2008.
20. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturvedi V, Ghannoum MA, Espinel-Ingroff A, Knapp CC, Ostrosky-Zeichner L, Pfaller MA, Sheehan DJ, Walsh TJ. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard—Second Edition (M38-A2). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2008.
21. Eliopoulos GM, Ambrose PG, Bradford PA, Craig WA, Cullen SK, Flamm RK, Friedrich LV, Jones RN, Marsik FJ, Motyl MR, Powell M, Powers JH, Rex JH, Sheldon AT, Talbot GH, Thrupp LD, Traczewski MM, Turnidge JD, Weinstein MP, Zimmer BL. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline—Third Edition. CLSI document M23-A3. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2008.
22. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg B-J, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 48:503-535, 2009

23. Espinel-Ingroff A, Fothergill AW, Ghannoum MA, Pfaller MA, Rex JH, Walsh TJ. Method for Antifungal Disk Diffusion Susceptibility Testing of Filamentous Fungi; Proposed Guideline, CLSI Document M51-P. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.
24. Rex JH, Ghannoum MA, Alexander BD, Andes DA, Brown SD, Diekema DJ, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Pfaller MA, Sheehan DJ, Walsh TJ. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Approved Guideline — Second Edition. CLSI document M44-A2. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.
25. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Prospective Survey of (1 → 3)-beta-D-Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting. *J Clin Microbiol* 2011; 49:58-61.
26. Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, Cuenca-Estrella M, Herbrecht R, Jacobs F, Kalin M, Kibbler CC, Lortholary O, Martino P, Meis JF, Muñoz P, Odds FC, De Pauw BE, Rex JH, Roilides E, Rogers TR, Ruhnke M, Ullmann AJ, Uzun O, Vandewoude K, Vincent JL, Donnelly JP. European expert opinion on the management of invasive candidiasis in adults. *Clin Microbiol Infect* 17(Suppl. 5):1–12, 2011.
27. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. *Clin Infect Dis* 52(S5):S397–S428, 2011.
28. Rex JH, Eisenstein EI, Jeff Alder J, Goldberger M, Meyer R, Dane A, Ian Friedland I, Knirsch C, Sanhai WR, John Tomayko J, Cindy Lancaster C, Jackson J. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. *The Lancet Infectious Diseases* 13:269-75, 2013. (Impact factor 19.97)
29. Rex JH, Eisenstein EI, Jeff Alder J, Goldberger M, Meyer R, Dane A, Ian Friedland I, Knirsch C, Sanhai WR, John Tomayko J, Cindy Lancaster C, Jackson J. Addressing the need for new antibacterials (letter). *The Lancet Infectious Diseases* 13:834-5, 2013. (Impact factor 19.97)
30. Tomayko JF, Rex JH, Tenero DM, Goldberger M, Eisenstein BI. The challenge of antimicrobial resistance: New regulatory tools to support product development. *Clin Pharm Ther* 96:166-168, 2014.
31. Rex JH, Martini LG, Bates S, Lefroy J, Lawrence J, Garner C. Antibiotic development in the UK urgently needs a new economic model. *The Financial Times*, November 16, 2015, accessed online at <http://www.ft.com/cms/s/0/863fa682-8969-11e5-90de-f44762bf9896.html#axzz3rdspdcN>.
32. Jinks T, Lee N, Sharland M, Rex J, Gertler N, Diver M, Jones I, Jones K, Mathewson S, Chiara F, Farrar J. A time for action: Antimicrobial resistance needs global response. *Bull World Health Org* 94(8):558–558A, 2016.
33. McDonnell AM, Rex JH, Goossens H, Bonten M, Fowler VG, Dane A. Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. *Clinical Infectious Diseases*. 2016;63 (Suppl. 2):S57-59.
34. Boucher HW, Ambrose PG, Chambers HF, Ebricht RH, Jezek A, Murray BE, Newland JG, Ostrowsky B, Rex JH. White Paper: Developing Antimicrobial Drugs for Resistant Pathogens and Unmet Needs. *J Infect Dis*, DOI: <https://doi.org/10.1093/infdis/jix211>, 2017.
35. Årdal C, Baraldi E, Ciabuschi F, Outtersson K, Rex JH, Piddock LJV, and Findlay D for the DRIVE-AB Steering Committee. To the G20: incentivising antibacterial research and development. *Lancet Infect Dis* S1473-3099(17)30404-8, 2017. (Impact factor 19.97)
36. Årdal C, Findlay D, Savic M, Carmeli Y, Gyssens I, Laxminarayan R, Outtersson K, Rex JH. DRIVE-AB Report: Revitalizing the antibiotic pipeline. <http://drive-ab.eu/>, 2017.
37. van Belkum A, Bachmann T, Lüdke3 G, Lisby JG, Kahlmeter G, Mohess A, Becker K, Hays JP, Woodford N, Mitsakakis K, Moran-Gilad J, Vila J, Peter H, Rex JH, Dunne WM, and the JPIAMR AMR-RDT Working Group on Antimicrobial Resistance and Rapid Diagnostic Testing. Developmental Roadmap for Antimicrobial Susceptibility Testing Systems. *Nat Rev Microbiol* 17(1):51-62, 2019. (Impact Factor 26.8)
38. Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, Torres A, Cammarata S, Rex JH, Powers JH, Fleming T, Loutit J, and Hoffmann S for the Foundation for the National Institutes of Health Biomarkers Consortium HABP/VABP Project Team. Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. *J Infect Dis* doi:10.1093/infdis/jiy578, 2019.
39. Hays, J. P., K. Mitsakakis, S. Luz, A. van Belkum, K. Becker, A. van den Bruel, S. Harbarth, J. H. Rex, G. S. Simonsen, G. Werner, V. Di Gregori, G. Lüdke, T. van Staa, J. Moran-Gilad, T. T. Bachmann and on behalf of the JPIAMR AMR-RDT consortium (2019). "The successful uptake and sustainability of rapid infectious disease and antimicrobial

resistance point-of-care testing requires a complex 'mix-and-match' implementation package." *European Journal of Clinical Microbiology & Infectious Diseases* 38: <https://doi.org/10.1007/s10096-10019-03492-10094>.

40. Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, et al. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. *The Journal of Infectious Diseases*. 2019;219(10):1536-44.
41. Weiss E, Zahar J-R, Alder J, Asehnoune K, Bassetti M, Bonten MJM, et al. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. *Clinical Infectious Diseases* 69 (11):1912–1918, <https://doi.org/10.1093/cid/ciz093>, 2019.
42. Slavin M, Chen YC, Cordonnier C, Cornely O, Cuenca-Estrella, M, Donnelly P, Groll AH, Lortholary O, Marty F, Nucci, M, Rex J, Rijnders B, Thompson G, Verweij P, White L, Hargreaves R, Harvey E, Maertens J When to change treatment of acute invasive aspergillosis: an expert viewpoint, Volume 77, Issue 1, January 2022, Pages 16–23, <https://doi.org/10.1093/jac/dkab317>.

Commented [Rex20]: If you add, adjust paper counts above.

D. Group Authorship

1. Sharkey PK, Kauffman CA, Graybill JR, Stevens DA, Hostetler JS, Dismukes WE, and the NIAID Mycoses Study Group. Itraconazole treatment of sporotrichosis. *Am J Med* 95:279-285, 1993.
2. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingróff A, Hogan P, Sheehan D, and the CLSI Subcommittee for Antifungal Testing. Wild-Type MIC Distributions, Epidemiological Cutoff Values and Species-Specific Clinical Breakpoints for Fluconazole and *Candida*: Time for Harmonization of CLSI and EUCAST Broth Microdilution Methods. *Drug Resist Updates* 13:180-95, 2010.
3. Pfaller MA, Diekema DJ, Andes D, Arendrup MD, Brown SD, Motyl M, Perlin DS, and the CLSI Subcommittee for Antifungal Testing. Clinical Breakpoints for the Echinocandins and *Candida* Revisited: Integration of Molecular, Clinical, and Microbiological Data to Arrive at Species-Specific Interpretive Criteria. *Clin Micro Reviews* 14:164-76, 2011.

Commented [Rex21]: If you add, adjust paper counts above.

E. Book Chapters

1. Rex JH. Sporotrichosis in GL Mandell, RG Douglas, and JE Bennett (eds.), *Principles and Practice of Infectious Diseases*, 4th Ed., pp. 2321-2324, 1994.
2. Cohen DM, Rex JH. Antifungal therapy in Schlossberg DM (ed.), *Current Therapy of Infectious Disease* pp. 609-612, 1996.
3. Rex JH. Approach to the treatment of systemic fungal infections in Kelley WN (ed.), *Kelley's Textbook of Internal Medicine*, 3rd Ed., pp. 1853-1855, 1996.
4. Martins MD, Rex JH. Antifungal therapy in Parrillo JE (ed.). *Current Therapy in Critical Care Medicine*, 3rd Ed., pp. 295-300, 1997.
5. Lozano-Chiu M, Rex JH. Resistance to antifungal agents in Ajello L and Hay RJ (eds.). *Topley & Wilson's Microbiology and Microbial Infections*, 9th Ed., Volume 4, pp. 177-187, 1998.
6. Rex JH, Sobel JD, Powderly WB. *Candida* infections in Yu VL, Jr., Merigan TC, Jr., and Barriere SL (eds.). *Antimicrobial Therapy & Vaccines* pp. 1054-1076, 1998. Williams & Wilkins, Baltimore, MD.
7. Rex JH, Okhuysen PC. *Sporothrix schenckii* in GL Mandell, RG Douglas, and JE Bennett (eds.), *Principles and Practice of Infectious Diseases*, 5th Ed., pp. 2695-2698, 2000.
8. Rodriguez LJ, Anaissie EJ, Rex JH. Pneumonia due to *Candida* species in Sarosi GA and Davies SF (eds.), *Fungal Disease of the Lung*, 3rd Ed., pp. 115-122, 2000.
9. Rex JH, Pappas PG. Hematogenously Disseminated Fungal Infections in Anaissie EJ, Pfaller MA, McGinnis M (eds.), *Clinical Mycology* pp. 554-565, 2003.
10. Pappas PG, Rex JH. Therapeutic approaches to *Candida* sepsis in Mandell GL and Tunkel A (eds.), *Current Infectious Diseases Reports*, 1:245-252, 2000.
11. Rex JH. Approach to the treatment of systemic fungal infections in Kelley WN (ed.), *Kelley's Textbook of Internal Medicine*, 4th Ed., 2279–2281, 2000.
12. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents in Scolnick EM (ed.), *Drug Discovery and Design (A volume of Advances in Protein Chemistry)* 58:423-475, 2001.

13. Ostrosky-Zeichner L, Rex JH. Antifungal and antiviral therapy in Parrillo JE and Dellinger RP (eds.), *Critical Care Medicine: Principles of Diagnosis and Management in the Adult*, 2nd Ed., pp. 1069–1088, 2001.
14. Arikan S and Rex JH. Antifungal Drugs in *Manual of Clinical Microbiology*. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC (eds.), 8th Ed., pp. 1859-1868, 2003.
15. Cunha BA, Rex JH. Empiric therapy based on clinical syndrome in Cunha BA (ed.): *Antibiotic Essentials* (2nd ed.), pp. 18-142, 2003.
16. Cunha BA, Schoch PE, Rex, JH. Initial therapy of isolates pending susceptibility testing in Cunha BA (ed.): *Antibiotic Essentials* (2nd ed.), pp. 143-185, 2003.
17. Wagner KF, Cunha BA, Rex, JH. Parasites, fungi, and unusual organisms in Cunha BA (ed.): *Antibiotic Essentials* (2nd ed.), pp. 186-225, 2003.
18. Ostrosky-Zeichner L, Rex JH. Filamentous fungi in C. Glen Mayhall (ed.): *Hospital Epidemiology and Infection Control*, 3rd Ed. pp. 705-708, 2004, 2003.
19. Cunha BA, Rex JH. Empiric therapy based on clinical syndrome in Cunha BA (ed.): *Antibiotic Essentials* (3rd ed.), pp. 18-142, 2004.
20. Cunha BA, Schoch PE, Rex, JH. Initial therapy of isolates pending susceptibility testing in Cunha BA (ed.): *Antibiotic Essentials* (3rd ed.), pp. 143-185, 2004.
21. Wagner KF, Cunha BA, Rex, JH. Parasites, fungi, and unusual organisms in Cunha BA (ed.): *Antibiotic Essentials* (3rd ed.), pp. 186-225, 2004.
22. Cunha BA, Castanheira D, Owens C, Owens RC, Rex JH, Kaplan MH. Antimicrobial drug summaries in Cunha BA (ed.): *Antibiotic Essentials* (3rd ed.), pp. 293-403, 2004.
23. Rex JH, Sobel JD, Powderly WB. *Candida* infections in the HIV-infected individual in Singh N, Swindells S, & Shafer R (eds.): *HIV Clinical Manual*, Pittsburgh, Esun Technologies, 2003.
24. Rex JH, Stevens DA. Antifungal agents in GL Mandell, JE Bennett, and R Dolin (eds.), *Principles and Practice of Infectious Diseases*, 6th Ed., pp. 502-514, 2005.
25. Rex JH, Okhuysen PC. *Sporothrix schenckii* in GL Mandell, JE Bennett, and R Dolin (eds.), *Principles and Practice of Infectious Diseases*, 6th Ed., 2984-2988, 2005.
26. Cunha BA, Rex JH. Empiric therapy based on clinical syndrome in Cunha BA (ed.): *Antibiotic Essentials* (4th ed.), pp. 18-132, 2005. Physician's Press, Royal Oak, Michigan.
27. Cunha BA, Schoch PE, Rex, JH. Initial therapy of isolates pending susceptibility testing in Cunha BA (ed.): *Antibiotic Essentials* (4th ed.), pp. 143-185, 2005. Physician's Press, Royal Oak, Michigan.
28. Wagner KF, Cunha BA, Rex, JH. Parasites, fungi, and unusual organisms in Cunha BA (ed.): *Antibiotic Essentials* (4th ed.), pp. 186-225, 2005. Physician's Press, Royal Oak, Michigan.
29. Cunha BA, Castanheira D, Owens C, Owens RC, Rex JH, Kaplan MH. Antimicrobial drug summaries in Cunha BA (ed.): *Antibiotic Essentials* (4th ed.), pp. 365-486, 2005. Physician's Press, Royal Oak, Michigan.
30. Rex JH, Sobel JD, Powderly WB. *Candida* infections in Yu VL, Jr., Weber R., and Raoult D (eds.). *Antimicrobial Therapy & Vaccines* pp. 1001-1032, 2002 (2nd Ed.). Williams & Wilkins, Baltimore, MD.
31. Arikan S and Rex JH. Resistance to Antifungal Agents in Topley & Wilson's *Microbiology and Microbial Infections*, 10th Ed., pp. 168-181, 2005.
32. Cunha BA, Nichols RL, Rex JH, Cleri DJ, Schlossberg, D. Empiric therapy based on clinical syndrome in Cunha BA (ed.): *Antibiotic Essentials* (5th ed.), pp. 18-142, 2006. Physician's Press, Royal Oak, Michigan.
33. Cunha BA, Schoch PE, Rex, JH. Initial therapy of isolates pending susceptibility testing in Cunha BA (ed.): *Antibiotic Essentials* (5th ed.), pp. 143-185, 2006. Physician's Press, Royal Oak, Michigan.
34. Wagner KF, McGuire, JH, Cunha BA, Rex JH. Parasites, fungi, and unusual organisms in Cunha BA (ed.): *Antibiotic Essentials* (5th ed.), pp. 186-225, 2006. Physician's Press, Royal Oak, Michigan.
35. Cunha BA, Torres DC, Rex JH, Kaplan MH. Antimicrobial drug summaries in Cunha BA (ed.): *Antibiotic Essentials* (5th ed.), pp. 365-497, 2006. Physician's Press, Royal Oak, Michigan.
36. Arikan S and Rex JH. Antifungal Drugs in *Manual of Clinical Microbiology*. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC (eds.), 9th Ed., pp. 1949-60, 2007.
37. Cunha BA, Nichols RL, Rex JH, Cleri DJ, Schlossberg, D. Empiric therapy based on clinical syndrome in Cunha BA (ed.): *Antibiotic Essentials* (6th ed.), pp. 18-142, 2007. Physician's Press, Royal Oak, Michigan.

38. Cunha BA, Schoch PE, Buttone EJ, Rex JH. Initial therapy of isolates pending susceptibility testing *in* Cunha BA (ed.): Antibiotic Essentials (6th ed.), pp. 143-185, 2007. Physician's Press, Royal Oak, Michigan.
39. Wagner KF, McGuire JH, Cunha BA, Rex JH, Bottone EJ. Parasites, fungi, and unusual organisms *in* Cunha BA (ed.): Antibiotic Essentials (6th ed.), pp. 186-225, 2007. Physician's Press, Royal Oak, Michigan.
40. Cunha BA, Torres DC, Kubiak DW, Rex JH, Kaplan MH. Antimicrobial drug summaries *in* Cunha BA (ed.): Antibiotic Essentials (6th ed.), pp. 389-530, 2007. Physician's Press, Royal Oak, Michigan.
41. Ostrosky-Zeichner L, Rex JH. Antifungal and antiviral therapy *in* Parrillo JE and Dellinger RP (eds.), Critical Care Medicine: Principles of Diagnosis and Management in the Adult, 3rd Ed., pp. 1089-1109, 2007.
42. Arthington-Skaggs BA and Rex JH. Resistance to Antifungal Agents *in* Fong IW & Drlica K (Eds.) Antimicrobial Resistance and Implications for the 21st Century, pp. 325-370, 2008.
43. Cunha BA, Nichols RL, Rex JH, Cleri DJ, Schlossberg D. Empirical therapy based on clinical syndrome *in* Cunha BA (ed.): Antibiotic Essentials (7th ed.), pp. 18-142, 2008. Physician's Press, Royal Oak, Michigan.
44. Cunha BA, Schoch PE, Bottone EJ, Rex JH. Initial therapy of isolates pending susceptibility testing *in* Cunha BA (ed.): Antibiotic Essentials (7th ed.), pp. 142-185, 2008. Physician's Press, Royal Oak, Michigan.
45. Wagner KF, McGuire JH, Cunha BA, Rex JH, Bottone EJ. Parasites, fungi, and unusual organisms *in* Cunha BA (ed.): Antibiotic Essentials (7th ed.), pp. 186-225, 2008. Physician's Press, Royal Oak, Michigan.
46. Cunha BA, Torres DC, Kubiak DW, Rex JH, Kaplan MH. Antimicrobial drug summaries *in* Cunha BA (ed.): Antibiotic Essentials (7th ed.), pp. 401-551, 2008. Physician's Press, Royal Oak, Michigan.
47. Arian S and Rex JH. Fungal Drug Resistance Assays *in* Mayers DL, Sobel JD, Ouellete M, Lerner S (eds.): Antimicrobial Drug Resistance Handbook, pp. 1145-1160, 2009. Humana Press, Totowa, New Jersey.
48. Rex JH, Stevens DA. Antifungal agents *in* GL Mandell, JE Bennett, and R Dolin (eds.), Principles and Practice of Infectious Diseases, 7th Ed., pp. 549-563, 2009.
49. Rex JH, Okhuysen PC. *Sporothrix schenckii* *in* GL Mandell, JE Bennett, and R Dolin (eds.), Principles and Practice of Infectious Diseases, 7th Ed., pp. 3271-3275, 2009.
50. Cunha BA, Nichols RL, Rex JH, Cleri DJ, Schlossberg D. Empiric therapy based on clinical syndrome *in* Cunha BA (ed.): Antibiotic Essentials (8th ed.), pp. 17-172, 2009. Physician's Press, Burlington, Massachusetts.
51. Cunha BA, Schoch PE, Bottone EJ, Rex JH. Initial therapy of isolates pending susceptibility testing *in* Cunha BA (ed.): Antibiotic Essentials (8th ed.), pp. 173-223, 2009. Physician's Press, Burlington, Massachusetts.
52. Wagner KF, McGuire JH, Cunha BA, Rex JH, Bottone EJ. Parasites, fungi, and unusual organisms *in* Cunha BA (ed.): Antibiotic Essentials (8th ed.), pp. 224-271, 2009. Physician's Press, Burlington, Massachusetts.
53. Cunha BA, Torres DC, Kubiak DW, Rex JH, Kaplan MH. Antimicrobial drug summaries *in* Cunha BA (ed.): Antibiotic Essentials (8th ed.), pp. 478-659, 2009. Physician's Press, Burlington, Massachusetts.
54. Walsh TJ, Roilides E, Rex JH, McGinnis MR: Mucormycosis and Entomophthoromycosis *in* Guerrant RL, Walker DH, Weller PF (Eds.): Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd Ed., pp. 597-602, 2011.
55. Cunha BA, Bruschi JL, Nichols RL, Papanicolaou G, Hage JE, Koff RS, Rex JH, Cleri DJ, Cunha CB, Fischer SA, Schlossberg D. Empirical therapy based on clinical syndrome *in* Cunha BA (ed.): Antibiotic Essentials (10th ed.), pp. 17-182, 2011. Jones & Bartlett Learning, Burlington, Massachusetts.
56. Cunha BA, Schoch PE, Bottone EJ, Rex JH, Strollo S, Syed U. Antibiotic susceptibility profiles and initial therapy of isolates pending susceptibility testing *in* Cunha BA (ed.): Antibiotic Essentials (10th ed.), pp. 183-250, 2011. Jones & Bartlett Learning, Burlington, Massachusetts.
57. Wagner KF, McGuire JH, Cunha BA, Hage JE, Kubiak DW, Mickail N, Rex JH, Kaplan MH. Parasites, fungi, and unusual organisms *in* Cunha BA (ed.): Antibiotic Essentials (10th ed.), pp. 251-298, 2011. Jones & Bartlett Learning, Burlington, Massachusetts.
58. Cunha BA, Torres DC, Hage JE, Kubiak DW, Rex JH, Kaplan MH. Antimicrobial drug summaries *in* Cunha BA (ed.): Antibiotic Essentials (10th ed.), pp. 519-713, 2011. Jones & Bartlett Learning, Burlington, Massachusetts.
59. Ostrosky-Zeichner L, Rex JH. Filamentous fungi *in* C. Glen Mayhall (ed.): Hospital Epidemiology and Infection Control, 4th Ed. pp. 628-631, 2012.
60. Cunha BA, Bruschi JL, Nichols RL, Papanicolaou G, Hage JE, Koff RS, Rex JH, Cleri DJ, Cunha CB, Fischer SA, Schlossberg D. Empirical therapy based on clinical syndrome *in* Cunha BA (ed.): Antibiotic Essentials (11th ed.), pp. 17-184, 2012. Jones & Bartlett Learning, Burlington, Massachusetts.

61. Cunha BA, Schoch PE, Bottone EJ, Rex JH, Strollo S, Syed U. Antibiotic susceptibility profiles and initial therapy of isolates pending susceptibility testing *in* Cunha BA (ed.): *Antibiotic Essentials* (11th ed.), pp. 185–252, 2012. Jones & Bartlett Learning, Burlington, Massachusetts.
62. Wagner KF, McGuire, JH, Cunha BA, Hage JE, Kubiak DW, Mickail N, Rex JH, Kaplan MH. Parasites, fungi, and unusual organisms *in* Cunha BA (ed.): *Antibiotic Essentials* (11th ed.), pp. 253–300, 2012. Jones & Bartlett Learning, Burlington, Massachusetts.
63. Cunha BA, Torres DC, Hage JE, Kubiak DW, Rex JH, Kaplan MH. Antimicrobial drug summaries *in* Cunha BA (ed.): *Antibiotic Essentials* (11th ed.), pp. 521–718, 2012. Jones & Bartlett Learning, Burlington, Massachusetts.

Commented [Rex22]: If you add, adjust counts above.

F. Abstracts:

1. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. Interferon gamma (IFN-gamma) therapy augments the *in vitro* ability of chronic granulomatous disease (CGD) neutrophils (PMNS) to damage *Aspergillus* hyphae. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. 939, 1990.
2. Rex JH, Hanson LH, Amantea, MA, Stevens DA, Bennett JE. Standardization of a fluconazole bioassay and correlation with results obtained by HPLC. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. 1084, 1990.
3. Rex JH, Larsen RA, Bennett JE. Catastrophic visual loss due to *C. neoformans* meningitis. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. 842, 1992.
4. Rex JH, Bennett JE, Sugar A, Edwards JE, Washburn RG, Van der Horst C, Dine AP, Webb CD, and the Candidemia Study Group. Fluconazole vs. amphotericin B for treatment of candidemia: Results of a multicenter, randomized trial. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. 805, 1993.
5. Cohen DA, Bhalla S, Anaissie E, Rex JH. Interferon- γ and granulocyte-colony stimulating factor protect some but not all neutrophil functions from the effects of storage and irradiation. 31st Annual Meeting of the Infectious Diseases Society of America, Abstract No. 228, 1993.
6. Pfaller MA, Buschelman B, Lancaster M, Rinaldi M, Espinel-Ingroff A, Rex JH. Multicenter comparison of a colorimetric microbroth dilution method with the reference macrodilution method for *in vitro* susceptibility testing of yeast isolates. 94th General Meeting of the American Society for Microbiology, Abstract No. C-470, 1994.
7. Pfaller MA, Bale M, Lancaster M, Rinaldi M, Espinel-Ingroff A, Rex JH. Selection of candidate quality control (QC) isolates and tentative QC ranges for *in vitro* susceptibility testing of yeast isolates using NCCLS proposed standard methods. 94th General Meeting of the American Society for Microbiology, Abstract No. C-471, 1994.
8. Rex JH, Nelson PW, Webb CD, the NIAID MSG, and the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole vs. amphotericin B for treatment of non-neutropenic patients with candidemia. XII Congress of the International Society for Human and Animal Mycology (Adelaide, Australia), Abstract S11.1, 1994.
9. King RT, Rex JH, Tamayo L, Miller JW, Garcia CA. *Candida* endophthalmitis (CE): A prospective study of its incidence and epidemiology in intensive care unit (ICU) patients. Association for Research in Vision and Ophthalmology. Abstract No. 3417, 1994.
10. Martins MD, Cowart RE, Anaissie JE, Rex JH. Role of lymphocytes in host defense against *Aspergillus fumigatus* (AF). 32nd Annual Meeting of the Infectious Diseases Society of America, Abstract No. 307, 1994.
11. Cohen DM, Bhalla S, Anaissie EJ, Rex JH. PMN obtained by leukapheresis from granulocyte-CSF (G) stimulated donors: Studies of function after isolation, irradiation, storage, and cytokine treatment. 32nd Annual Meeting of the Infectious Diseases Society of America, Abstract No. 296, 1994.
12. Dignani MC, Anaissie EJ, Hester JP, Vartivarian SE, O'Brien S, Rex JH, Bodey GP. A phase I/II study of granulocyte-colony stimulating factor (G-CSF) elicited white blood cell transfusions (WBCTx) for neutropenia-related fungal infections. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. G54, 1994.
13. Wanger A, Mills K, Rex JH. Comparison of ETest and macrobroth dilution for antifungal susceptibility testing. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. D20, 1994.
14. Pfaller MA, Rex JH, Barry AL. Strain variation and antifungal susceptibility among *Candida* blood stream isolates. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. J105, 1994.

15. Cohen DM, Savary CA, Martins MD, Cowart RE, Graziutti ML, Anaissie EJ, SE Vartivarian, and Rex JH. Binding of lymphocytes to *Aspergillus* conidia: Inhibition by antibodies to mammalian adhesion molecules. 33rd Annual Meeting of the Infectious Diseases Society of America, Abstract No. 519, 1995.
16. Martins MD, Cohen DM, Savary CA, Cowart RE, Graziutti ML, Vartivarian SE, Anaissie EJ, Rex JH. Role of lymphocytes in host defense against *Aspergillus fumigatus* (*A. fumigatus*). 33rd Annual Meeting of the Infectious Diseases Society of America, Abstract No. 522, 1995.
17. Nelson PW and Rex JH. In vitro activity of L-733560 against putatively amphotericin B- and fluconazole-resistant *Candida* isolates. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. F99, 1995.
18. Wanger A, Mills K, Nelson PW, and Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant *Candida* isolates 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. E71, 1995.
19. Lozano-Chiu M, Rex JH, Nelson PW. Lot-to-lot variability of Antibiotic Medium 3 (AM3) when used for susceptibility testing of *Candida* to amphotericin B (AmB) by M27P. 96th General Meeting of the American Society for Microbiology, Abstract F84, 1996.
20. Oefinger PE, Goldsmith TL, Atkins JT, Ericsson CD, Johnson PJ, Rex JH, Cocanour CS, Butler J. Modifications of antibiotic usage within a tertiary care teaching hospital. 96th General Meeting of the American Society for Microbiology, Abstract A1, 1996.
21. Nelson PW, Lozano-Chiu M, Rex JH. In vitro activity of L-743,872 against putatively amphotericin B- and fluconazole-resistant *Candida* isolates. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract F28, 1996.
22. Martins MD, Nelson PW, Lozano-Chiu M, Rex JH. Incidence of symptomatic & asymptomatic carriage of fluconazole-resistant *Candida* in the oropharynx of HIV-infected patients. 34th Annual Meeting of the Infectious Diseases Society of America, Abstract 82, 1996.
23. Rex JH, Nelson PW, Lozano-Chiu M, Paetznick VL, Anaissie EJ. Fluconazole MICs for *Candida* are more predictive of outcome *in vivo* when read after 24 hours rather than 48 hours. 34th Annual Meeting of the Infectious Diseases Society of America, Abstract 74, 1996.
24. Graziutti ML, Rex JH, Cowart R, Anaissie EJ, Savary CA. Lymphocyte response to *Aspergillus fumigatus*. 34th Annual Meeting of the Infectious Diseases Society of America, Abstract 236, 1996.
25. Lozano-Chiu M, Ghannoum MA, Belanger P, Rex JH. Effect of media on detection of amphotericin B-resistant *Cryptococcus neoformans*. 97th General Meeting of the American Society for Microbiology, Abstract C-251, 1997.
26. Lozano-Chiu M, Rex JH. Evaluation of a colorimetric method for detecting amphotericin B-resistant *Candida*. 97th General Meeting of the American Society for Microbiology, Abstract C-252a, 1997.
27. Lozano-Chiu M, Nelson PW, Paetznick V, Rex JH. Activity of voriconazole vs. *Candida*: Effects of incubation time, *Candida* species, and fluconazole susceptibility. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract E-87, 1997.
28. Nelson PW, Lozano-Chiu M, Rex JH. A disk diffusion method for determining the susceptibility of *Candida* spp. to L-743,872. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract F-79, 1997.
29. Lozano-Chiu M, Ghannoum MA, Rex JH. Detection of amphotericin B-resistant *Cryptococcus neoformans* is enhanced by use of Etest and/or Antibiotic Medium 3. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract D-141, 1997.
30. Fleming RV, Anaissie EJ, Kantarjian HM, Savary C, Rex JH. Inteferon-gamma plus granulocyte-colony stimulating factor in the treatment of refractory fungal infections: A pilot study. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract G-31, 1997.
31. Anaissie E, Kuchar, R, Rex JH, Summerbell R, Walsh T. The hospital water system as a reservoir for *Fusarium*. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-94, 1997.
32. Tome L, Rex JH, Graziutti MG, Anaissie EJ, Savary CA. Binding of *Aspergillus fumigatus* conidia to A549 pneumocytes is inhibited by laminin, fibronectin, and RGDS peptide. 35th Annual Meeting of the Infectious Diseases Society of America, Abstract 122, 1997.

33. Graziutti ML, Savary CA, Przepiorka D, Cowart RE, Rex JH. Comparison of the efficiency of monocytes and dendritic cells as stimulators of lymphocyte proliferative response to *Aspergillus* and *Candida*. 35th Annual Meeting of the Infectious Diseases Society of America, Abstract 123, 1997.
34. Pappas PG, Rex JH, Hamill RJ, Larsen RA, Powderly WG, Lee J, Horowitz H, Kauffman CA, Chapman SW, Rubin RH, NIAID-MSG Candidiasis Subproject. Current trends in nosocomial candidemia: Results of a large multicenter Study. 35th Annual Meeting of the Infectious Diseases Society of America, Abstract 13, 1997.
35. Rodriguez LJ, King RT, Garcia CA, Rex JH. Frequency, natural history, & etiology of retinal lesions in ICU patients with sepsis. 35th Annual Meeting of the Infectious Diseases Society of America, Abstract 671, 1997.
36. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of symptomatic oropharyngeal candidiasis, carriage of *Candida albicans*, and fluconazole resistance in HIV patients. 35th Annual Meeting of the Infectious Diseases Society of America, Abstract 138, 1997.
37. Smith NH, Graviss EA, Hashmey R, Lozano-Chiu M, Rex JH, Hamill R. Multi-drug resistant cryptococcal meningitis in an AIDS patient. 35th Annual Meeting of the Infectious Diseases Society of America, Abstract 529, 1997.
38. Savary CA, Rex JH, Graziutti ML, Tomasovic SP, Przepiorka D, Pellis NR, Pierson DL. Characteristics of dendritic cell maturation in the NASA bioreactor. 1997 Annual Meeting of the American Society for Gravitational and Space Biology, Abstract #143, November, 1997, San Antonio, TX.
39. Arikan S, Lozano-Chiu M, Paetznick V, Gordon D, Wallace T, Rex JH. In Vitro Activity Of Liposomal Nystatin Compared With Amphotericin B And Fluconazole Against Clinical *Candida* Isolates. 98th General Meeting of the American Society for Microbiology, Abstract No. C-280, 1998.
40. Lozano-Chiu M, Arikan S, Paetznick V, Anaissie EJ, Loebenberg D, Rex JH. Successful treatment of murine fusariosis with Schering 56592. 98th General Meeting of the American Society for Microbiology, Abstract No. F-101, 1998.
41. Coffman SL, Pfaller MA, Messer SA, Chen Y-S, Wang J, Arikan S, Lozano-Chiu M, Rex JH, Rennie R, Heffner T, Sand C, Yamane N. Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing. 98th General Meeting of the American Society for Microbiology, Abstract No. C-272, 1998.
42. Savary CA, Graziutti ML, Przepiorka D, Braunschweig I, Rex JH. Dendritic cell response to pathogenic fungi. Keystone Symposia: Cellular and Molecular Biology of Dendritic Cells, 1998.
43. Arikan S, Paetznick VL, Arizmendi A, Lal L, Khyne TA, Lozano-Chiu M, Wallace T, Bazemore S, Rex JH. Comparative Murine Pharmacokinetics of Polyene Antifungal Agents. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-079, 1998.
44. Lozano-Chiu M, Arikan S, Martin-Diez FM, Paetznick V, Rodriguez-Tudela JL, Rex JH. Reliability of Antibiotic Medium 3 Agar and E-test for Detection of Amphotericin B-Resistant Isolates of *Candida* spp.: Results of a Collaborative Two-Center Study. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-018, 1998.
45. Lozano-Chiu M, Arikan S, Martin-Diez FM, Paetznick V, Rodriguez-Tudela JL, Rex JH. A Two-Center Study of Antibiotic Medium 3 Broth for Detection of Amphotericin B-Resistant Isolates of *Candida* spp. (CAND) and *Cryptococcus neoformans*. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-019b, 1998.
46. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Activity of Amphotericin B, Itraconazole, and Voriconazole Against *Aspergillus* and *Fusarium*. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-019, 1998.
47. Pappas PG, Rex JH, Lee J, Hamill R, Larsen R, Powderly W, Horowitz H, Hyslop N, Mangino J, Webster R, Thomas C. Candidemia in the United States: Therapeutic approaches and the emergence of non-*albicans* *Candida* species. 36th Annual Meeting of the Infectious Diseases Society of America, Abstract 320, 1998.
48. Marr KA, Rustad, TR, Rex JH, White TC. The trailing endpoint phenotype in antifungal susceptibility testing is pH-dependent. 36th Annual Meeting of the Infectious Diseases Society of America, Abstract 357, 1998.
49. Rex JH, Lozano-Chiu M, Paetznick V, Khyne AT, Nangia S, Arizmendi A, Riser L, Pappas PG and the Co-Investigators of the NIAID MSG Candidiasis Subproject. Susceptibility testing of current *Candida* bloodstream isolates from Mycoses Study Group (MSG) collaborative study #34: Isolates of *C. krusei* are often resistant to both fluconazole and amphotericin B. 36th Annual Meeting of the Infectious Diseases Society of America, Abstract 324, 1998.

50. Graziutti ML, Savary SA, Przepiorka D, Vadhan-Raj S, Braunschweig I, Rex JH. In vitro reconstitution of the lymphocyte proliferative response against fungal antigens one month after peripheral blood stem cell transplantation by the addition of dendritic cells. 36th Annual Meeting of the Infectious Diseases Society of America, Abstract 339, 1998.
51. Rex JH, Anaissie EJ, Boutati E, Estey E, Kantarjian H. Antifungal Prophylaxis reduces invasive fungal infections in acute myelogenous leukemia—A retrospective review of 833 episodes of neutropenia in 322 adults. 36th Annual Meeting of the Infectious Diseases Society of America, Abstract 347, 1998.
52. Sobel J, Rex J, Stevens D, Wheat J, Saag M, Chapman S, Kauffman C, Galgiani J, Dismukes W. Practice Guidelines for the treatment of fungal diseases. 36th Annual Meeting of the Infectious Diseases Society of America, Abstract S2, 1998.
53. Mendoza M, Fisher V, Allen L, Wanger A, Cocanour C, Rex JH. Multidrug-resistant *Acinetobacter baumannii* infection in a surgical intensive care unit: Epidemiology, DNA-typing, and risk factors for nosocomial spread. 26th Annual Educational and International Conference of the Association for Professionals in Infection and Epidemiology, Baltimore, MD, Abstract M18, 1999.
54. Fisher V, Mendoza M, Rex JH. Risk factors for methicillin-resistant *Staphylococcus aureus* surgical site infection following coronary artery bypass surgery. 26th Annual Educational and International Conference of the Association for Professionals in Infection Control and Epidemiology, Baltimore, MD, Abstract M17, 1999.
55. Marr KA, Rustad TR, Rex JH, White TC. The elimination of trailing in *Candida* species by lowering media pH may be related to production of hyphae. Abstract C37, ASM Conference on Candida and Candidiasis, March 1-4, 1999, Charleston, SC.
56. Anaissie EJ, Stratton SL, Summerbell RC, Monson TP, Rex JH, Walsh TJ. *Aspergillus* species aerosols in hospitals: Showering as a potential mode of exposure. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 1908, 1999.
57. Ascioğlu S, De Pauw B, Bille J, Crokaert F, Denning DW, Donnelly P, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis J, Patterson T, Rex JH, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Analysis of Definitions Used In Clinical Research on Invasive Fungal Infections (IFI): Consensus Proposal for New, Standardized Definitions. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 1639, 1999.
58. Arikian S, Lozano-Chiu M, Paetznic V, Rex JH. In Vitro Susceptibility Testing Methods for Caspofungin Against *Aspergillus* and *Fusarium* Isolates. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J-160, 1999.
59. Steele K, Rex JH, Tharp ER, Fisher V. Reduction of Surgical Site Infections Following Aortocoronary Bypass By Implementation of New CDC Guidelines for Prevention of SSI. 37th Annual Meeting of the Infectious Diseases Society of America, Abstract 501, 1999.
60. Mohr J, Wright S, Rex J, Goldsmith T. Discovery of a *Pseudomonas aeruginosa* outbreak in the intensive care unit as a result of the preparation of a unit specific antibiogram. Twenty-Sixth Annual Midwest Pharmacy Residents Conference, 2000.
61. Dignani MC, Damiano C, Graziutti M, Paetznic V, Vera-Ocampo C, Rex J. *Candida* spp. susceptibility to fluconazole during a three-year period of fluconazole use at one onco-hematologic institution. Proceedings of the 14th Congress of the International Society for Human and Animal Mycology, Abstract 375, Buenos Aires, Argentina.
62. Hamill RJ, Pappas PG, Rex JH, Lee JY, Horowitz H, Kauffman CA, Hyslop N, Larsen RA, Stein DK, Graviss EA, Thomas CJ, and the Mycoses Study Group. Multicenter surveillance of non-*albicans* candidemia. 38th Annual Meeting of the Infectious Diseases Society of America, Abstract 36, 2000.
63. Ostrosky-Ziechner L, Paetznic VL, Rodriguez JR, Chen E, Rex JH. In-vitro antifungal susceptibilities of Trichosporon species. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #935, 2000.
64. Lozano-Chiu M, Paetznic VL, Rodriguez JR, Rex JH. Anti-Candida Activity of the Sordarin Derivatives GW471552, GW471558, GW506540, GW531920, and GW560849: Effect of Endpoint Rule and Incubation Time on MIC. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #192, 2000.
65. Ostrosky-Ziechner L, Paetznic VL, Mohr J, Rodriguez JR, Chen E, Sancak B, Rex JH. In-Vitro Antifungal Activity of FK-463 against *Candida* spp. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #197, 2000.

66. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. in vitro synergy studies with caspofungin and amphotericin B against *Aspergillus* and *Fusarium*. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #932, 2000.
67. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW. Use of the fluconazole (FLU) dose/MIC ratio to predict clinical outcome of oropharyngeal candidiasis (OPC). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #1419, 2000.
68. Ostrosky-Ziechner L, Bazemore SA, Paetznick VL, Rodriguez JR, Chen E, Wallace TL, Rex JH. Antifungal activity of isomeric forms of nystatin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #1956, 2000.
69. Uzun O, Ascioğlu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in cancer patients with breakthrough candidemia. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #705, 2000.
70. Anaissie EJ, Stratton SL, Summerbell RC, Rex J, Walsh TJ. Pathogenic *Aspergillus* species recovered from a hospital water system: A three-year prospective study. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #1321, 2000.
71. Anaissie EJ, Stratton SL, Rex J, Walsh TJ. Hospital water as the source of aspergillosis: Evidence for possible nosocomial transmission. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #1322, 2000.
72. Nates JL, Mendoza MP, Allison MR, Espinosa L, Rex JH. Reduction of Ventilator-Associated Pneumonia in a Neuro-Critical Care Unit. 30th International Meeting of the Society of Critical Care Medicine, Abstract #254/M160, 2000.
73. Mohr J, Wanger A, Goldsmith T, Rex J. Using Pharmacokinetic/pharmacodynamic indices to guide empiric therapy against *Pseudomonas aeruginosa* in a 700-bed private, university-affiliated teaching hospital. Abstract 133. American College of Clinical Pharmacy Annual Meeting, Tampa, FL. 2001.
74. Peninger M, Rex JH, Tidemann T, Brothers J, Brown G, Marciniak D, Miller M, Orford S, Shaver S, Fisher V, Septimus E. Cost-Benefit Of A Silver Alloy, Hydrogel-Coated Latex Urinary Catheter In A Large Healthcare System. 28th Annual Meeting of the Association for Practitioners of Infection Control, Abstract #023, 2001.
75. Pseudo-Outbreak Of Resistant *Pseudomonas aeruginosa* Related To Contaminated Bronchoscopes-August 1999. Wright SL, Peninger M, Fisher V, Wanger A, Vogelsong M, Rex JH. 28th Annual Meeting of the Association for Practitioners of Infection Control, Abstract #009, 2001.
76. Ostrosky-Zeichner L, Paetznick VL, Sancak B, Rodriguez JR, Rex JH. Correlation of minimum inhibitory concentrations and disk diffusion diameters for FK-463 in 403 bloodstream isolates of *Candida* spp. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 572, 2001.
77. Rex JH. Alternative Trial Designs for Testing Antifungal Agents. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 2005, 2001.
78. Rex JH, McGinnis M, Arikan S, Rodríguez-Adrián L, Kirsch M. Building a Medical Education Website: Lessons Learned From The DoctorFungus Website. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 273, 2001.
79. Paphitou NI, Paetznick VL, Ostrosky-Zeichner L, Rodriguez JR, Chen E, Rex JH. In vitro activity of investigational triazoles against *Trichosporon* spp. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 814, 2001.
80. Paphitou NI, Paetznick VL, Ostrosky-Zeichner L, Rodriguez JR, Chen E, Rex JH. In Vitro Activity of Investigational Triazoles against *Fusarium*: Effects of Inoculum size, and Time of Reading on Broth Microdilution Susceptibility Test Results. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 573, 2001.
81. Arikan S, Paetznick VL, Rex JH. Comparison of Disk Diffusion and Microdilution Broth Susceptibility Testing of Caspofungin against *Aspergillus* and *Fusarium*. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 571, 2001.
82. Edmond M, McClish D, Massie T, Wiblin RT, Kauffman C, Welage L, Goff D, Rex JH, Schuster M, Wenzel R. Risk factors for nosocomial candidemia among patients in eight surgical intensive care units. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 1464, 2001.
83. Saeki F, Ridge RJ, Finkelman MA, Ketchum PA, and Rex JH. Application of a Glucan-Specific *Limulus* Amebocyte Lysate Serum Assay for Diagnosis of Invasive Fungal Infections. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 841, 2001.

84. Mattiuzzi G, Estey E, Rex JH, Lim J, Cortes J, Faderl S, Giles F, Thomas D, Kontoyiannis D, Kantarjian H. Intravenous Itraconazole for Prophylaxis of Invasive Fungal Infections in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 831, 2001.
85. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards J, Brass C, Chapman S, Horowitz H, Zervos M, Vazquez JA, McKinsey D, Kett D, Simmons B, Lee J, Mautner L, Chu TC, Panzer H, and the Candidemia Study Group. A randomized & blinded multicenter trial of high-dose fluconazole + placebo vs. fluconazole + amphotericin B as treatment of candidemia in non-neutropenic patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 681a, 2001.
86. Cuenca-Estrella M, Moore C, Barchiesi F, Bille J, Chryssanthou E, Denning DW, Donnelly JP, Dromer F, Dupont B, Rex JH, Richardson MD, Sancak B, Verweij PE, Rodriguez-Tudela JL, & The AFST Subcommittee of EUCAST. Multicenter evaluation of the proposed EUCAST Antifungal Susceptibility Testing Method. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 569, 2001.
87. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz H, Powderly WG, Hyslop N, Kauffman CA, Chapman SW, Mangino J, Lee J, for the NIAID-MSG Candidiasis Subproject. Three Year Survey of Regional and Temporal Trends in Fluconazole Resistance Among Bloodstream *Candida* spp. Isolates from the United States. 39th Annual Meeting of the Infectious Diseases Society of America, Abstract 643, 2001.
88. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz H, Powderly WG, Hyslop N, Kauffman CA, Chapman SW, Mangino J, Lee J, for the NIAID-MSG Candidiasis Subproject. Antifungal Susceptibility Survey of 2,000 Bloodstream *Candida* Isolates from the United States. 39th Annual Meeting of the Infectious Diseases Society of America, Abstract 642, 2001.
89. Anaissie EJ, Owens S, Dignani MC, Lee CK, Rex J, Walsh T. Cleaning bathrooms: A novel approach to reducing patient exposure to aerosolized *Aspergillus* spp. Blood 2001;98:207A.
90. Evaluation of oral soft tissue lesions in ventilated patients. Moretti AJ, Flaitz CM, Peninger M, Rex JH, Milano M, Harrison, N, Nates J. 56th Annual Meeting of the American Academy of Oral Medicine, 2002, published in Oral Surgery Oral Medicine Oral Pathology 93(4): 427, 2002.
91. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Developing criteria for risk-stratified prophylaxis of invasive candidiasis in the ICU. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1239, 2002.
92. Ostrosky-Zeichner L, Matar M, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro synergy testing of anidulafungin and micafungin in combination with amphotericin B against *Aspergillus* spp. and *Fusarium* spp. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1816, 2002.
93. Odabasi Z, Mattiuzzi G, Ostrosky-Zeichner L, Estey E, Kantarjian H, Rex JH. Detection of (1->3)- β -D-Glucan in the serum of leukemia patients with invasive fungal infections. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-902, 2002.
94. Matar M, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, and Rex JH. Correlation between Etest, Disk diffusion, and Microdilution Antifungal Susceptibility Testing of Fluconazole and Voriconazole. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1494, 2002.
95. Andrade R, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, and Rex JH. Synergistic Antifungal Effect of Fluconazole and CDR1/2 Efflux Pump Inhibitors: Insights into the Trailing Growth Phenomenon. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-223, 2002.
96. Suleiman J, Della Negra M, Llanos-Cuentas A, Ticona E, Rex JH, Buell DN. Open-label study of micafungin in the treatment of esophageal candidiasis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-892, 2002.
97. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis: Experience from open-label protocols. 40th Annual Meeting of the Infectious Diseases Society of America, Abstract 352, 2002.
98. Mattiuzzi GN, Riehl T, Pierce S, Rex JH, Cortes J, Giles F, Garcia-Manero G, Verstovseki S, Malekshamran HK, Kantarjian H, Estey E. Intravenous itraconazole versus caspofungin for prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. American Society Of Hematology 44th Annual Meeting And Exposition. Abstract 452, 2002.

99. Grimes CZ, Peninger M, Ostrosky-Zeichner L, Clifton G, Nates JL, and Rex JH. Comparison of three definitions to determine ventriculostomy-related ventriculitis rates in neurological trauma patients. 30th Annual Meeting of the Association for Practitioners of Infection Control, Abstract 43, 2003.
100. Peninger M, Ostrosky-Zeichner L, Fisher V, Wright S, Grimes CZ, Wanger A, Rex JH. Infection control during a devastating flood event: Recovery and lessons learned. 30th Annual Meeting of the Association for Practitioners of Infection Control, Verbal Abstract (unnumbered), 2003.
101. Fisher V, Rex JH, Ackert-Burr C, Peninger M, Ostrosky-Zeichner L. Operating room staff attitudes toward brushless vs. traditional surgical hand scrubbing. 30th Annual Meeting of the Association for Practitioners of Infection Control, Abstract 111, 2003.
102. Ostrosky-Zeichner L, Mohr J, Finkel KW, Rodriguez JR, Rex JH. Pharmacokinetics and safety evaluation of IV itraconazole/cyclodextrin in stable hemodialysis patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-2056, 2003.
103. Philip A, Odabasi Z, Rodriguez JR, Paetznick VL, Chen E, Ostrosky-Zeichner L, Rex JH. In vitro synergy testing of anidulafungin with itraconazole and voriconazole against *Aspergillus* spp. and *Fusarium* spp. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-988, 2003.
104. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Rex JH, Ostrosky-Zeichner L. (1->3)-beta-D-glucan for the diagnosis of invasive fungal infections in leukemia patients on antifungal prophylaxis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1028, 2003.
105. Philip A, Odabasi Z, Mattiuzzi G, Paetznick VL, Rex JH, Ostrosky-Zeichner L. SysCan3 for the detection of anti-Candida antibodies for the diagnosis of invasive candidiasis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-2060, 2003.
106. Ostrosky-Zeichner L, Philip A, Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Comparison of colony forming unit counts and quantitative PCR (qPCR) conidial equivalent measurement in a murine model of fusariosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-362, 2003.
107. Arikan S, Sancak B, Tuncer S, Rex JH. PCR-based identification of *Trichosporon asahii* by direct amplification of the colony. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1023, 2003.
108. Ostrosky-Zeichner L, Alexander B, Kett D, Vazquez J, Pappas P, Saeki F, Ketchum PA, Wingard JR, Schiff RA, Tamura H, Finkelman MA, Rex JH. Multicenter Clinical Evaluation of the (1->3) β -D-Glucan Assay (GlucateLL™) as an Aid to Diagnosis of Invasive Fungal Infections in Humans. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1034a, 2003.
109. Fisher V, Peninger M, Tharp E, Warters RD, Rex JH, Ostrosky-Zeichner L. Four-Year Sustainability of a Post-Coronary Artery Bypass Graft Surgical Site Infection Prevention Program. 14th Annual Meeting of the Society for Healthcare Epidemiology of America, Philadelphia, PA, Abstract #322, 2004.
110. Kullberg BJ, Pappas P, Ruhnke M, Viscoli C, Cleary JD, Rubinstein E, Church LWP, Brown JM, Rex JH, Hilton F, Oborska I, Hodges M, Schlamm HT, Sobel J. Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment of candidemia in non-neutropenic patients. 14th European Congress of Clinical Microbiology and Infectious Diseases, Abstract O245, 2004.
111. Ostrosky-Zeichner L, Rex JH, Paetznick VL, Rodriguez JR, Chen E, Pappas PG, Dismukes WE. Lack of correlation of in vitro checkerboard-based antifungal combination results with clinical outcomes. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M1679, 2004.
112. Mohr J, Paetznick V, Rodriguez J, Finkelman M, Cocanour C, Rex JH, Ostrosky-Zeichner L. A prospective pilot survey of beta-glucan seropositivity and its relationship to invasive candidiasis in the surgical ICU. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-168, 2005.
113. Oude Lashof AML, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Rex JH, Kullberg BJ. Safety and tolerability of voriconazole compared to amphotericin B followed by fluconazole in patients with candidaemia and baseline renal insufficiency. 14th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, Abstract P977, 2007.
114. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan D, Walsh TJ. Wild Type Minimum Inhibitory Concentration (MIC) Distribution and Epidemiological Cutoff Values (ECVs) for *Aspergillus fumigatus* and

- Triazoles Using Clinical and Laboratory Standards Institute (CLSI) Method. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1716/485, 2009.
115. Andes DR, Safdar N, Baddley J, Playford G, Rex J, Sobel J, Nucci M, Kullberg B, Pappas P. Impact Of Therapy On Mortality Across Candida Spp In Patients With Invasive Candidiasis From Randomized Clinical Trials: A Patient Level Analysis. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-1312, 2010.
 116. Li J, Lovick S, Sunzel M, Dane A, Rex J. Evaluation of the Classification and Regression Tree (CART) method to estimate clinical PK/PD targets. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract A1-1756, 2011.
 117. Hope W, McEntee L, Johnson A, Farrington N, Whalley S, Santoyo-Castelazo A, Birch M, Law D, Kennedy T, Heep M, Rex J. Pharmacodynamics of F901318 against *Aspergillus fumigatus* in a rabbit model of invasive pulmonary aspergillosis (IPA). 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April, 2017
 118. Lakota EA, Bulik CC, Bader JC, Bhavnani SM, Dale GE, Wallnoefer A, Rex JH, Ambrose PG. Mind the Gap: A Pharmacokinetic-Pharmacodynamic (PK-PD) Evaluation of Ertapenem for Patients with Ventilator-Associated Bacterial Pneumonia (VABP). ASM Microbe, New Orleans, 1-5 June 2017 (3 June 2017 abstract, session 264).
 119. Seyedmousavia S, Chang Y, Law D, Birch M, Rex JH, Kwon-Chung KJ. Efficacy of dihydroorotate dehydrogenase inhibitor F901318 against invasive aspergillosis due to *Aspergillus fumigatus*, *A. nidulans* and *A. tanneri* in profoundly neutropenic and chronic granulomatous disease murine models. 8th Advances Against Aspergillosis, Lisbon, Portugal, 1-3 Feb 2018 (submitted abstract).
 120. Talbot GH, Das A, Torres A, Powers JH, Cush S, Dane A, Wible M, Echols R, Cammarata S, Rex JH, Fleming T, and Hoffmann S for the Biomarkers Consortium (BC) of the Foundation for the National Institutes of Health (FNIH) HABP/VABP Project Team. Alternatives to the All-cause Mortality (ACM) Endpoint for the Study of Hospital-Acquired Bacterial Pneumonia(HABP) and Ventilator-Associated Bacterial Pneumonia (VABP). 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 20-25 April 2018, Abstract #3570.
 121. Wiederhold N, Najvar L, Bocanegra R, Olivo M, Birch M, Law D, Rex J, Patterson T. The Orotomide F901318 is Efficacious in a Murine Model of Coccidioides Meningitis. 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 20-25 April 2018 (abstract).
 122. GH Talbot, A Das, S Cammarata, JH Powers, S Cush, A Dane, M Wible, R Echols, A Torres, T Fleming, JH Rex, S Hoffmann for the Biomarkers Consortium (BC) of the Foundation for the National Institutes of Health (FNIH) HABP/VABP Project Team. A Novel, Evidence-based Endpoint for Studies of Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP). ASM Microbe 2018, 7-11 June 2018, Atlanta, GA (abstract).
 123. Wiederhold NP, Patterson H, Birch M, Law D, Rex JH. Evaluation of the In vitro Activity of Olorofim Against *Fusarium* Species. 9th Trends in Medical Mycology (TIMM-9), 11-14 October 2019, Nice, France (abstract).
 124. Seyedmousavi S, Chang Y, Law D, Birch M, Rex JH, Kwon-Chung KJ. In vivo efficacy of olorofim against systemic infection caused by *Scedosporium apiospermum*, *Pseudallescheria boydii*, and *Lomentospora prolificans* in neutropenic CD-1 mice. 9th Trends in Medical Mycology (TIMM-9), 11-14 October 2019, Nice, France (abstract).
 125. Buil JB, Oliver JD, Law L, Tehupeiory-Kooreman M, Rex JH, Hokken MWJ, Melchers WJG, Birch M, Verweij PE. Molecular mechanism and frequency of olorofim resistance in *Aspergillus fumigatus*. 9th Trends in Medical Mycology (TIMM-9), 11-14 October 2019, Nice, France (abstract).
 126. Buil JB, Oliver JD, Birch M, Law L, Rex JH, Tehupeiory-Kooreman M, van de Lee HAL, Melchers WJG, Verweij PE. In vitro susceptibility of olorofim against 1,682 clinical *Aspergillus* isolates. 9th Trends in Medical Mycology (TIMM-9), 11-14 October 2019, Nice, France (abstract).
 127. Buil JB, Oliver JD, Law L, Tehupeiory-Kooreman M, Rex JH, Hokken MWJ, Melchers WJG, Birch M, Verweij PE. Molecular mechanism and frequency of olorofim resistance in *Aspergillus fumigatus*. 9th Trends in Medical Mycology (TIMM-9), 11-14 October 2019, Nice, France (submitted abstract).
 128. Chen S, RaiL NJ, Cunneen S, Cornelissen K, Rex J, Chris Heath C. A case of *Lomentospora prolificans* (LoPro) treated with the novel antifungal olorofim. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, 18-21 April 2020 (abstract 2585).
 129. Maertens M, Rijnders B, Thompson G, Fitton L, Rex J, Chen S. An open-label study of the novel antifungal olorofim for the treatment of invasive mould disease in patients with limited treatment options: an overview of the study design,

- patient demographics, and range of pathogens identified. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, 18-21 April 2020 (abstract).
130. Tio, SY, Thursky K, Ng G, Rex JH, Carney D, Slavin M. Olorofim for a case of severe disseminated *Lomentospora prolificans* infection. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, 18-21 April 2020 (abstract 118).
 131. Thompson GR, Fitton L, Harvey E, Rex J. Disseminated coccidioidomycosis treated with olorofim. 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, 18-21 April 2020 (abstract 3203).
 132. Cornelissen K, Rex JH, Allen G, Steiner J, Kennedy T. An Open-Label Study in Healthy Volunteers to Evaluate the Effect of Fluconazole upon the Pharmacokinetics of Olorofim. 31st European Congress of Clinical Microbiology and Infectious Diseases (online) 9-12 Jul 2021 (abstract 01080).
 133. Cornelissen K, Law D, Kennedy T, Rex JH, Townley S, Johnson S, Ayrton J. Tissue distribution of (¹⁴C)-olorofim following intravenous dosing in the rat. 31st European Congress of Clinical Microbiology and Infectious Diseases (online) 9-12 Jul 2021 (abstract 01077).
 134. Walsh T, Witting B, Robb K, Finkelsztejn E, Spagnoletti J, Rex J, Small C. Treatment of *Scedosporium* Mycetoma Refractory to Voriconazole with Olorofim. 31st European Congress of Clinical Microbiology and Infectious Diseases (online) 9-12 Jul 2021 (abstract).
 135. Zerbe C, Rex J, Sabo M, Shoham S. Improvement of *Aspergillus udagawae* Infection with Olorofim Therapy in the setting of Chronic Granulomatous Disease. 31st European Congress of Clinical Microbiology and Infectious Diseases (online) 9-12 Jul 2021 (abstract).
 136. Morrissey O, Garlick J, Gaffney N Harvey E, Rex J. Long-term Use of Olorofim in the Treatment of *Scedosporium apiospermum* Chest Wall Infection. 31st European Congress of Clinical Microbiology and Infectious Diseases (online) 9-12 Jul 2021 (abstract).
 137. Thompson GR, Colamartino J, Trigg K, Harvey E, Rex J: Treatment of Disseminated Coccidioidomycosis with Olorofim. Mycoses Study Group – Education & Research Consortium (MSGERC) 2022, 7-9 Sep 2022, Albuquerque, NM. Abstract.
 138. Cornelissen K, Wright J, Cristinacce A, Galbraith H, Bruggeman R, Maertens J, Thompson GR, Chen SC-A, Rex, J. Olorofim (OLO) for treatment of invasive mould infections in patients with limited or no treatment options: PK data from a Phase 2b open-label study (NCT03583164, Study 32). IDWeek 2022, 18-22 Oct 2022, Abstract #595.
 139. Cornelissen K, Newell P, Rex JH, Galbraith H, Isreal S, Bush J. An Open-Label Study in Healthy Volunteers to Determine the Absolute Bioavailability of, the Effect of Food and Dosing by Nasogastric Tube upon the Pharmacokinetics of a Single Oral Dose of Olorofim (OLO). IDWeek 2022, 18-22 Oct 2022, Abstract #594.
 140. Maertens J, Thompson GR, Spec A, Hammond S, Rijnders B, White PL, Cornely O, Fitton L, Dane A, Rex J, Chen S. Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: Interim results from a Phase 2b open-label study (NCT03583164, Study 32). IDWeek 2022, 18-22 Oct 2022, Abstract #754.
 141. Maertens J, Verweij P, Lanuza E, Harvey E, Dane A, Zinzi D, Rex J, Chen SC. Olorofim for the treatment of invasive mould infections (IMI) in patients with limited or no treatment options: Comparison of interim results from a Phase 2b open-label study with outcomes in historical control populations (NCT03583164, Study 32). IDWeek 2022, 18-22 Oct 2022, Abstract #870.
 142. Monica Slavin, Johan Maertens, Sharon Chen, Christopher Heath, Martin Hoenigl, Orla Morrissey, Hong Nguyen, David Paterson, George Thompson, Stephen Walsh, Daniela Zinzi, Lesley Fitton, Harvey Emma, and John Rex. Outcomes of invasive fungal infections (IFI) due to *Lomentospora prolificans* infections treated with olorofim. 33rd European Congress of Clinical Microbiology and Infectious Diseases (Copenhagen) 14-18 April 2021 (abstract O1135).
 143. Sarah Hammond, Chris Heath, Martin Hoenigl, Andrej Spec, Daniela Zinzi, Emma Harvey, and John Rex. Outcomes in a clinical trial cohort of patients with invasive *Scopulariopsis* infections treated with olorofim.. 33rd European Congress of Clinical Microbiology and Infectious Diseases (Copenhagen) 14-18 April 2021 (abstract O1141).
 144. Methée Chayakulkeeree, Anupop Jitmuang, Emma Harvey, Daniela Zinzi, John H. Rex. Successful Treatment of Refractory Invasive Aspergillosis with a Novel Antifungal Agent Olorofim in a Leukemia Patient: A Case Report. 11th Trends in Medical Mycology (TIMM-11), 20-23 October 2023, Athens, Greece (abstract P389).

145. Daniela Zinzi, Mike Birch, Emma Harvey, John Rex, Johan Maertens, Jason Oliver, Sharon Chen. Outcomes of invasive fungal disease in a subgroup of patients receiving olorofim/azole combination in an open label salvage study. 11th Trends in Medical Mycology (TIMM-11), 20-23 October 2023, Athens, Greece (abstract P412).
146. Karen Cornelissen, Daniela Zinzi, John H Rex, Hal Galbraith, Joel Neutel, Thomas Marbury. A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects with Hepatic Impairment. 11th Trends in Medical Mycology (TIMM-11), 20-23 October 2023, Athens, Greece (abstract P437).
147. Karen Cornelissen, Daniela Zinzi, John H Rex, Hal Galbraith, Kwabena Ayesu. A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects with Renal Impairment. 11th Trends in Medical Mycology (TIMM-11), 20-23 October 2023, Athens, Greece (abstract P439).
148. Andrej Spec, Mike Birch, Corinne Pinder, Emma Harvey, Daniela Zinzi, John Rex. Clinical outcome in a US patient with *A. ustus* complex pulmonary invasive aspergillosis treated with olorofim in a Phase 2b study (NCT03583164). 11th Trends in Medical Mycology (TIMM-11), 20-23 October 2023, Athens, Greece (abstract P471).
149. Cornelissen K, Rex JH, Zinzi D, Galbraith H, Burt HJ. Assessment of body weight upon PK of olorofim in patients with invasive mould infections. IDWeek 2024 (Los Angeles), 16-19 Oct 2024, Abstract P-1238.
150. Cornelissen K, Rex JH, Zinzi D, Bruggemann R, Wright J. Systemic exposure of olorofim in children with invasive fungal infections. IDWeek 2024 (Los Angeles), 16-19 Oct 2024, Abstract P-1239.
151. Fariba M. Donovan, George R Thompson, Royce H. Johnson, Rasha A. Kuran, Thomas F Patterson, Martin Hoenigl, Joanna M. Schaenman, Shmuel Shoham, Steven M Holland, Monica K Sikka, Andrej Spec, Mark Bresnik, John N Galgiani, John H Rex. Novel Antifungal Olorofim Use in Intractable CNS and Non-CNS Disseminated Coccidioidomycosis. IDWeek 2024 (Los Angeles), 16-19 Oct 2024, Presentation 95.

Commented [Rex23]: If you add adjust abstract count!

G. Major Presentations at National and International Meetings

1. XII Congress of the International Society for Human and Animal Mycology, March 1994, Adelaide, Australia. Speaker in symposium "Update on the management of fungal infections," with lecture entitled "Fluconazole vs. amphotericin B as therapy of candidemia in non-neutropenic patients."
2. 31st Annual William J. Holloway Infectious Disease Symposium of the Medical Society of Delaware, May, 1994, Wilmington, DE. Lecture entitled "Recent advances in the management of systemic *Candida* infections."
3. 94th General Meeting of the American Society for Microbiology, May 1994, Las Vegas, NV. Speaker in symposium entitled "Research developments in the clinical mycology laboratory," with lecture entitled "Antifungal susceptibility testing."
4. 24th Annual Meeting of the Society for Critical Care Medicine, February 1995, San Francisco, CA. Speaker in symposium entitled "Diagnosis and treatment of fungal infectious in critically-ill patients," with lecture entitled "Treatment of *Candida* bloodstream infections."
5. Focus on Fungus V (sponsored by the University of Texas Health Science Centers of San Antonio and Houston), March 1995, San Francisco, CA. Lecture entitled "Recent advances in the management of *Candida* bloodstream infections."
6. FDA Antiviral and Antifungal Drug Division Advisory Board, April, 1995, Bethesda, MD. Lecture entitled "Design issues in therapy trials for invasive candidiasis."
7. International Advisory Board for the Management of Invasive Candidiasis (sponsored by Harbor-UCLA Medical School), April, 1995, Torrance, CA.
8. 95th General Meeting of the American Society for Microbiology, May 1995, Washington, DC. Speaker in symposium entitled "Contemporary issues in antifungal susceptibility testing: Beyond the NCCLS reference method," with lecture entitled "Pitfalls in establishing clinical relevance for antifungal susceptibility testing."
9. Trends in Fungal Infections III (sponsored by the European Organization for Research on Treatment of Cancer), September 7-9, 1995, Brussels, Belgium. Lecture entitled "Treatment of serious *Candida* infections."
10. 25th Annual Meeting of the Society for Critical Care Medicine, February 1996, New Orleans, LA. Speaker in symposium entitled "Management of infections in the critically-ill patient: Focus on *Candida* and *Enterococci*," with lecture entitled "Epidemiology, risk factors, and treatment strategies for invasive candidiasis in the critically-ill patient."
11. ASM Conference on *Candida* and Candidiasis: Biology, Pathogenesis, and Management, March 24-27, 1996, San Diego, CA. Speaker in symposium entitled "Candidiasis: Epidemiology and treatment," with lecture entitled "Disseminated *Candida* syndromes in non-neutropenic patients: current status and future directions."

12. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1996, New Orleans, LA. Convenor of symposium entitled “Antifungal drug resistance: Problems & perspectives,” with lecture entitled “Current therapeutic approaches to antifungal drug resistance.”
13. 34th Annual Meeting of the Infectious Diseases Society of America and the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1996, New Orleans, LA. Speaker in symposium entitled “Frontiers of antimicrobial susceptibility testing: When procedures meet reality,” with lecture entitled “Antifungal susceptibility testing: The clinical relevance of resistance *in vitro*.”
14. 34th Annual Meeting of the Infectious Diseases Society of America, September 1996, New Orleans, LA. Co-convenor of a *Meet the Professor* session entitled “Management of fungal infections.”
15. Focus on Fungus VII (sponsored by the University of Texas Health Science Center—San Antonio), March 1997, San Antonio, TX. Lecture entitled “Point-counterpoint: Management of vascular catheters in candidemia.”
16. 97th General Meeting of the American Society for Microbiology, May 1997, Miami Beach, FL. Co-convenor of symposium entitled “Epidemiology and control of medically important fungi,” with lecture entitled “Antifungal resistance.”
17. 8th European Congress of Clinical Microbiology and Infectious Diseases, May 1997, Lausanne, Switzerland. Co-convenor of symposium entitled “Susceptibility testing of yeasts,” with lecture entitled “Antifungal susceptibility testing: New NCCLS interpretive guidelines.”
18. 13th Congress of the International Society for Human and Animal Mycology, June 1997, Parma, Italy. Organizer and co-convenor of a workshop entitled “Alternative Endpoints and Trial Designs for Clinical Trials of Antifungal Agents: Current Status, Future Directions.”
19. 13th Congress of the International Society for Human and Animal Mycology, June 1997, Parma, Italy. Co-convenor of symposium entitled “The role of immunoreconstitution in the management of refractory opportunistic fungal infections,” with lecture entitled “Immunity to fungal infections.”
20. 13th Congress of the International Society for Human and Animal Mycology, June 1997, Parma, Italy. Speaker in symposium entitled “Antifungal drug resistance in pathogenic fungi,” with lecture entitled “Beyond *Candida* and azoles: Antifungal resistance in other settings.”
21. 13th Congress of the International Society for Human and Animal Mycology, June 1997, Parma, Italy. Speaker in symposium entitled “The growing importance of non-*albicans Candida* species as opportunistic pathogens,” with lecture entitled “Treatment of non-*albicans Candida* infections.”
22. 21st International Congress of Chemotherapy, Sydney, Australia, July 1997. Speaker in a symposium entitled “Laboratory Support for Diagnosis and Management of Fungal Infections,” with lecture entitled “Clinical Relevance of Antifungal Susceptibility Testing and Emerging Azole Resistance.”
23. 35th Annual Meeting of the Infectious Diseases Society of America, September 1997, San Francisco. Co-convenor of a symposium entitled “Molecular Strategies for Antifungal Therapy: New Approaches to Resistant Infections.”
24. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 1997. Speaker in a symposium entitled “Clinical Evaluation of Antifungals,” with lecture entitled “Problems and Solutions to Clinical Trial Design.”
25. 5th Deep Mycoses Forum, February, 1998, Tokyo, Japan. Lecture entitled “Treatment of invasive fungal infections: Lessons from susceptibility testing.”
26. Focus on Fungus VIII (sponsored by the University of Texas Health Science Center—San Antonio), March 1998, Orlando, FL. Lecture entitled “Point-counterpoint: Use of lipid-associated amphotericin B preparations.”
27. Transplant Infectious Disease World Congress (sponsored jointly by the American Society for Transplant Physicians, the Centers for Disease Control and Prevention, the International Immunocompromised Host Society, and the Transplantation Society, April, 1998, Orlando, FL. Lecture entitled “Itraconazole and fluconazole in the treatment of fungal infection in transplant patients.”
28. 8th International Congress on Infectious Diseases (sponsored by the International Society for Infectious Diseases), May, 1998, Boston, MA. Lecture entitled “Treatment of *Candida* infections: Lessons from susceptibility testing.”
29. 6th International Mycology Congress, August, 1998, Jerusalem, Israel. Lecture entitled “Antifungal resistance: The clinical relevance of resistance *in vitro*.”
30. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 1998. Co-convenor of a *Meet the Expert* session entitled “Management of fungal infections.”

31. 28th Annual Meeting of the Society for Critical Care Medicine, January 1999, San Francisco, CA. Speaker in symposium entitled "Update in Infectious Diseases," with lecture entitled "Antifungal agents in immunosuppressed patients: What is the role of lipid formulations of amphotericin B?"
32. ASM Conference on *Candida* and Candidiasis: Biology, Pathogenesis, and Management, March 1-4, 1999, San Diego, CA. Speaker in symposium entitled "Antifungal Resistance," with lecture entitled "Antifungal susceptibility testing: What we do and do not know."
33. 4th International Antifungal Drug Discovery and Development Summit, March 10-11, 1999, Princeton, NJ. Keynote address: "New antifungal agents: Current needs and barriers to development."
34. 9th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, April 18-20, 1999, San Francisco, CA. Organizer and chairman of workshop entitled "Emerging nosocomial fungi," with lecture entitled "Antifungal resistance."
35. 1999 Harold C. Neu Infectious Diseases Conference, May 20-23, 1999, Philadelphia, PA. Organizer and chairman of session entitled "Fungal infections," with lecture entitled "Pharmacodynamics of antifungal agents: Implications for interpretation of susceptibility testing and drug dosing."
36. IXth International Congress of Bacteriology and Applied Microbiology and IXth International Congress of Mycology, August 16-20, 1999, Sydney, Australia. Speaker in plenary session entitled "Fungal resistance in medicine, food, and biodeterioration," with lecture entitled "Relevance of fungal resistance in medicine."
37. IXth International Congress of Bacteriology and Applied Microbiology and IXth International Congress of Mycology, August 16-20, 1999, Sydney, Australia. Speaker in symposium entitled "Serious fungal infections: Present and future treatment strategies," with lecture entitled "Pushing the envelope: Pharmacodynamic insights and the potential utility of combination therapy."
38. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999. Co-convenor of a symposium entitled "New Frontiers in Antifungal Resistance."
39. 29th Annual Meeting of the Society for Critical Care Medicine, February 2000, Orlando, FL. Speaker in symposium entitled "Issues in Infectious Diseases," with lecture entitled "Anti-fungal Resistance: Is it a problem in the ICU?"
40. Focus on Fungus X (sponsored by the University of Texas Health Science Center—San Antonio), March 2000, Atlanta, FL. Lecture entitled "Invasive candidiasis: Species Old & New, Therapies Tried & True."
41. 14th Congress of the International Society for Human and Animal Mycology, May 2000, Buenos Aires, Argentina. Speaker in symposium entitled "Superficial and invasive infections caused by *Candida* and other emerging yeasts," with lecture entitled "Treatment of candidemia in the non-neutropenic host."
42. 14th Congress of the International Society for Human and Animal Mycology, May 2000, Buenos Aires, Argentina. Lecture entitled "Correlation between in vitro susceptibility test results and clinical response."
43. 38th Annual Meeting of the Infectious Diseases Society of America, September 2000, New Orleans, LA. Speaker in a symposium entitled "Formulary 2000," with a lecture entitled "Current and future antifungal agents."
44. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000. Speaker in a symposium entitled "New antimicrobials," with a lecture entitled "Echinocandin antifungal agents."
45. Focus on Fungus XI, March 2001, Washington, DC. Lecture entitled "Alternative Trial Designs and Evaluation Strategies for Studies of New Antifungal Agents."
46. 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Istanbul, Turkey, April 2001. Speaker and convenor of a symposium entitled "Transatlantic Controversies in the Management of Serious Fungal Infections," with a lecture entitled "Are we ready for prophylaxis in the ICU?"
47. 49th Annual Meeting of the Japanese Society of Chemotherapy, Yokohama, Japan, May 2001. Speaker in a symposium entitled "A new class of anti-fungal agent: Candins," with a lecture entitled "Current understanding and future expectations of Candins in antifungal therapy"
48. Trends in Invasive Fungal Infections 6, Prague, Czech Republic, October 2001. Speaker in a symposium entitled "Opening Plenary Session," with a lecture entitled "Animal Models—Are they of Clinical Relevance?"
49. 39th Annual Meeting of the Infectious Diseases Society of America, October 2001, San Francisco, CA. Speaker in a symposium entitled "New Antifungals: From Bench to Bedside," with a lecture entitled "Impact of Echinocandins."

50. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 2001. Speaker in a symposium entitled “Conundrums in Medical Mycology,” with a lecture entitled “Alternative Trial Designs for Testing Antifungal Agents.”
51. 1st Annual John E. Bennett Forum on Clinical Trial Design, New York City, January 2002. Lecture entitled “Licensure of agents for therapy of aspergillosis.”
52. Focus on Fungus XII, March 2002, Phoenix, AZ. Moderator of session entitled “Interesting Case Reports — An Interactive Session.”
53. 9th Annual Meeting of the Korean Society for Medical Mycology, July 2002, Seoul, Korea. Plenary lecture entitled “Antifungal Agents: Old Questions, New Tools, and New Questions.”
54. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002. Speaker in a symposium entitled “New Antifungal Drugs, New Choices,” with a lecture entitled “What is the role of combination antifungals?”
55. 40th Annual Meeting of the Infectious Diseases Society of America, October 2002, Chicago, IL. Moderator of and speaker in a symposium entitled “Formulary 2002,” with a lecture entitled “Voriconazole and other new azoles.”
56. 2nd Annual John E. Bennett Forum on Clinical Trial Design, New York City, January 2003. Lecture entitled “Design of the caspofungin v. placebo trial in (S)ICU patients and use of risk factors in trial design.”
57. 13th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Glasgow, United Kingdom, May 2003. Keynote lecture entitled “New opportunities in the therapy of fungal diseases.”
58. 15th Congress of the International Society for Human and Animal Mycology, May 2003, San Antonio, Texas. Keynote lecture entitled “Future of Medical Mycology: A Clinical View.”
59. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 2003. Convenor of a symposium entitled “Pharmacodynamics of Antifungals”
60. 9th Congress of the European Confederation of Medical Mycology and the 7th Trends in Invasive Fungal Infections, Amsterdam, The Netherlands, September 2003. Plenary lecture entitled “New Drug Discoveries.”
61. 41st Annual Meeting of the Infectious Diseases Society of America, October 2003, San Diego, CA. Poster review faculty.
62. ASM Conference on *Candida* and Candidiasis: Biology, Pathogenesis, and Management, March 18-21, 2004, Austin, TX. Keynote speaker with lecture entitled “Future Directions in Antifungal Discovery.”
63. Infectious Diseases Society of America — International Society of Anti-Infective Pharmacology — Food and Drug Administration co-sponsored Antimicrobial Drug Development Workshop, April 15-16, 2004, Washington, DC. Invited panelist.
64. 2004 Meeting of the British Society for Medical Mycology, 19-20 April 2004, Bradford, UK. Plenary lecture entitled “The future of medical mycology: An industry perspective.”
65. 3rd Annual Conference on Antimicrobial Resistance, June 2004, Washington, DC. Chair keynote symposium entitled “Developing treatments for infections with no market pull: The example of the medicines for malaria venture.”
66. National Institute of Allergy and Infectious Disease (NIAID)-sponsored summit on Antimicrobial Availability, August 19-20, 2004, Washington, DC. Invited speaker & panelist.
67. 42nd Annual Meeting of the Infectious Diseases Society of America, October 2004, Boston, MA. Poster review faculty.
68. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, November 2004. Presentation entitled “Current therapy of candidal infections.”
69. Focus on Fungal Infections 15, March 2005, Miami, FL. Keynote lecture entitled “Discovery and development of antimicrobial agents: Meeting the challenges of generic agents, regulatory guidelines, efflux pumps, and points between.”
70. Annual meeting of Danish Infectious Diseases Society, May 2005, Middelfart, Denmark. Keynote lecture entitled “Therapy for candidemia.”
71. 4th Annual Conference on Antimicrobial Resistance, June 2005, Washington, DC. Chair symposium entitled “Economics of Antimicrobial Resistance.”
72. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 2005. Chair a symposium entitled “Antifungal Susceptibility Testing” and give a presentation entitled “Susceptibility -- the CLSI approach.”

73. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 2005. Chair a symposium entitled “The ‘critical path’ to antimicrobial drug development” and give a presentation entitled “Drug development from the pharmaceutical side.”
74. Gordon Research Conference entitled “New Antibacterial Discovery & Development”, March 5-10, 2008, Ventura, CA. Invited speaker with a talk entitled “The Fourth Horseman, Pestilence.”
75. AbstrNijmegen European Mycology Therapy Consensus Panel, May 2006, Nijmegen. Participant, with talk entitled “Antifungal therapy in the ICU.”
76. 5th Annual Conference on Antimicrobial Resistance, June 2006, Washington, DC. Chair symposium entitled “Pharmacological predictors of outcome: Can they be used to treat or prevent resistance? What is their role in drug development?”
77. 44th Annual Meeting of the Infectious Diseases Society of America, October 2006, Toronto, Canada. Chair a symposium entitled “Antifungal Formulary 2006.”
78. 40th Anniversary Symposium of Paul-Ehrlich-Society for Chemotherapy, April 30-May 2007, Königswinter, Germany. Participant, with talk entitled “Industry perspective on development of new antimicrobial agents.”
79. 6th Annual Conference on Antimicrobial Resistance, June 2007, Washington, DC. Participant, with talk entitled “Drug resistance in fungal infections.”
80. 6th Annual Conference on Antimicrobial Resistance, June 2007, Washington, DC. Chair symposium entitled “Drug-resistant *Mycobacterium tuberculosis*: Looking Back, Looking Forward.”
81. 45th Annual Meeting of the Infectious Diseases Society of America, October 2007, San Diego, CA. Chair a symposium entitled “Update on Fungal Treatment Guidelines.”
82. Gordon Research Conference entitled “New Antibacterial Discovery & Development”, March 9-14, 2008, Lucca, Italy. Invited speaker with a talk entitled “Clinical considerations for a new antibiotic.”
83. Joint 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / 46th Annual Meeting of the Infectious Diseases Society of America, October 2008, Washington, DC. Chair a symposium entitled “Update on the Antifungal Formulary.” Invited speaker with a talk entitled “Perspectives of the Pharmaceutical Industry.”
84. Innovative Incentives for Effective Antibacterials, September 17, 2009, sponsored by the Swedish EU Presidency, Stockholm, Sweden. Invited speaker with a talk entitled “Perspectives of the Pharmaceutical Industry.”
85. Public Health Emergency Medical Countermeasures Enterprise, February 22-24, 2010, An Institute of Medicine Workshop sponsored by the Institute of Medicine, Washington, DC. Invited speaker for plenary session with a talk entitled “Commercial Challenges: Perspectives from big pharma.”
86. Public Health Emergency Medical Countermeasures Enterprise, February 22-24, 2010, An Institute of Medicine Workshop sponsored by the Institute of Medicine, Washington, DC. Panelist for a panel discussion entitled “Strategies to Improve Portfolio Management: Translating Basic Science.”
87. EFPIA (European Federation of Pharmaceutical Industries and Associations), 2010 Annual Meeting (21 June 2010), Chair a symposium entitled “Antibiotics - Re-energising R&D to meet society’s needs.”
88. Antibacterial Resistance and Diagnostic Device and Drug Development Research for Bacterial Diseases; A Public Workshop Co-Sponsored by the Food and Drug Administration, the National Institute of Allergy and Infectious Diseases, and the Infectious Diseases Society of America. July 26-27, 2010, Silver Spring, MD. Member of the program planning committee and an invited speaker with a talk entitled “Drug discovery: Industry perspective .”
89. 20th Annual Meeting of the Society of Infectious Diseases Pharmacists, 11 Sep 2010, Boston, MA. Invited speaker (Meet-the-Expert Session) with a talk entitled “Industry Perspective on the Antimicrobial Pipeline”
90. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, 12-15 Sep 2010, Boston, MA. Invited symposium speaker with a talk entitled “Does the Anti-infective Pharmaceutical Industry need a stimulus package?”
91. Workshop on Antibacterials, 7-8 Feb 2011, European Medicines Agency, London, UK. Team leader for EFPIA Antimicrobial Working Group Presentation team, presenter for discussion materials on “Development of Drugs for Skin Infections” and “Development of Drugs for Bacteremia.”
92. Advancing Regulatory Science for Medical Countermeasure Development: An Institute of Medicine Workshop sponsored by the Institute of Medicine, Washington, DC. Workshop Co-Chair.

93. 21st Annual European Conference on Clinical Microbiology and Infectious Diseases and the 27th International Conference on Chemotherapy 7-10 May 2011, Milan, Italy. Speaker in a symposium entitled “Antifungal drugs make me mad: Azoles vs. Candins” with a lecture entitled “Azoles.”
94. 21st Annual European Conference on Clinical Microbiology and Infectious Diseases and the 27th International Conference on Chemotherapy 7-10 May 2011, Milan, Italy. Convenor for a symposium entitled “Antifungal Management Strategies.”
95. 21st Annual European Conference on Clinical Microbiology and Infectious Diseases and the 27th International Conference on Chemotherapy 7-10 May 2011, Milan, Italy. Speaker in a symposium entitled “Bad Bugs Need Better Drugs” with a lecture entitled “The Search for New Tools: The R&D Challenge.”
96. Pew Trust-IDSAs-PhRMA workshop, “Reviving the Pipeline of Life-Saving Antibiotics: Exploring Solutions to Spur Innovation”, 22 Sep 2011, Washington, DC. Speaker in a session entitled “Overcoming Antibiotics’ Unique Scientific and Regulatory Challenges” with a lecture entitled “Overcoming the unique scientific and regulatory challenges of antibiotics (Industry Perspective).”
97. EU-US (European Commission, NIAID) workshop, “Challenges And Solutions In The Development Of New Diagnostic Tests To Combat Antimicrobial Resistance”, 28-29 Sep 2011, Brussels, Belgium. Keynote speaker with a lecture entitled “The importance of rapid diagnostics for advancing antibacterial development.”
98. Gordon Research Conference entitled “New Antibacterial Discovery & Development”, April 15-20, 2012, Lucca, Italy. Invited speaker with a talk entitled “Trial feasibility and relevance of endpoints - the industry view.”
99. Engelberg Center for Health Care Reform at the Brookings Institution workshop entitled “Facilitating Antibacterial Development”, May 9, 2012, Washington, DC. Invited speaker with a talk entitled “Novel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program — the Industry View.”
100. Clinical Trials Transformation Initiative-US FDA workshop entitled “Anti-Bacterial Drug Development: Issues in the Design of Trials in Patients with Unmet Need and in Patients with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia”, October 10-11, 2012, Arlington, VA. Invited speaker with a talk entitled “Novel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program” and panelist in a session entitled “Identifying potential solutions to development of drugs for unmet need.”
101. Workshop on Antibacterials, 25-26 October 2012, European Medicines Agency, London, UK. Team leader for EFPIA Antimicrobial Working Group Presentation team, presenter for discussion materials on “Diagnostics.”
102. Pew Trust workshop, “A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations,” 1 Jan 2013, Washington, DC. Speaker in a session entitled “Defining the Limited Population Regulatory Pathway: What It Is, What It Does, and Why It Is Needed.”
103. Engelberg Center for Health Care Reform at the Brookings Institution workshop entitled “Incentives for Change: Addressing the Challenges in Antibacterial Drug Development,” 27 Feb 2013, Washington, DC. Discussant.
104. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 10–13 September 2013, Denver, Colorado. Invited speaker in a symposium entitled “Using Pharmacokinetics-Pharmacodynamics to Set In Vitro Susceptibility Breakpoints” with a talk entitled “New pathways for antibiotics for highly resistant pathogens: The fundamental role of PK-PD in Tier B and Tier C development programs”
105. Aligning Incentives for Antibiotic Development and Use With Public Health Needs. Chatham House Centre on Global Health Security Roundtable, 2 Oct 2013. Panelist in session entitled “Integrating Incentives for Development with Incentives for Conservation.”
106. Antimicrobial Resistance: Incentivizing Change towards a Global Solution, Chatham House Centre on Global Health Security Workshop, 3-4 Oct 2013, London, UK. Invited speaker in a session entitled “New approaches to diagnosis and discovery” with a talk entitled “How can new diagnostics aid clinical trials?”
107. 6th Trends in Medical Mycology (TIMM-6), 11-14 October 2013, Copenhagen, Denmark. Plenary speaker with a talk entitled “The landscape of antifungal development, present and future.”
108. FDA Anti-infective Drugs Advisory Committee (AIDAC), 17 Oct 2013, Silver Spring, MD. Invited speaker with a presentation entitled “The integral role of PK-PD in the development and maintenance of interpretive criteria.”
109. Engelberg Center for Health Care Reform at the Brookings Institution workshop entitled “Modernizing antibacterial drug development and promoting stewardship”, Feb 7, 2014, Washington, DC. Invited panelist in a session entitled “Targeting drug development for patients with serious bacterial diseases and unmet medical needs.”

110. 6th Advances Against Aspergillosis, 27 Feb to 1 Mar 2014, Madrid, Spain. Invited speaker with a presentation entitled “New agents for aspergillosis: Development pathways and economic pull.”
111. 6th Advances Against Aspergillosis, 27 Feb to 1 Mar 2014, Madrid, Spain. Co-chair of a symposium entitled “Clinical and scientific future of early anti-*Aspergillus* agents.”
112. Development of New Antibacterial Products: Charting a Course for the Future, NIH-FDA-Sponsored Workshop, 30-31 July 2014, Bethesda, MD. Invited speaker in a session entitled “Streamlined Antibacterial Drug Development Pathways Targeting Unmet Need” with a talk entitled “A Comprehensive Framework to Address the Unmet Need for New Antibacterial Treatments.”
113. Development of New Antibacterial Products: Charting a Course for the Future, NIH-FDA-Sponsored Workshop, 30-31 July 2014, Bethesda, MD. Invited speaker in a session entitled “The Role of Diagnostic Tests—Current State and Utility in Antibacterial Drug Development” with a talk entitled “Industry Perspective.”
114. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, 5-9 September 2014, Washington, DC. Keynote speaker with a lecture entitled “Enabling drug discovery & development to address the crisis of antimicrobial resistance: New tools, new pathways, & remaining challenges.”
115. Coordinated Development of Diagnostics & Therapeutics, NIH-FDA-Sponsored Workshop, 24-25 September 2014, Bethesda, MD. Invited speaker with a talk entitled “Coordinated Diagnostics & Therapeutics: A Clinician Developer’s Overview.”
116. Engelberg Center for Health Care Reform at the Brookings Institution workshop entitled “Reinvigorating the oral antibacterial development pipeline,” November 20, 2014, Washington, DC. Invited speaker with a talk entitled “Challenges with oral antibacterials.”
117. FDA Anti-infective Drugs Advisory Committee (AIDAC), 4 Dec 2014, Hyattsville, MD. Invited speaker representing BIO (Biotechnology Industry Organization), with a presentation entitled “Balancing Expectations: Dataset Size vs. Feasibility: Implications for labeling.”
118. Bioinfect Conference 2014, 4 Dec 2014, Alderley Park, UK. Invited speaker with a presentation entitled “Commercial Models.”
119. Enabling Rapid Response with Medical Countermeasures to Mitigate Risk of Emerging Infectious Diseases, March 26-27, 2015, An Institute of Medicine Workshop sponsored by the Institute of Medicine, Washington, DC. Member of program committee, session chair, and speaker in a session entitled “Sustainability and Maintenance of Business Models to Ensure Rapid and Nimble Response to Emerging Threats.”
120. BIO Biotechnology Industry Organization Annual Convention, 15-18 June 2015, Philadelphia, PA. Panelist in an interactive symposium entitled “Redefining Infectious Disease: Bacteria in Health and Sickness.”
121. Mapping the treatment journey to inform the patient-centred development of antibiotics and diagnostics, a workshop sponsored by the Wellcome Trust, 16-17 July 2015, London, UK. Panelist in a session entitled “A physician’s treatment reality: examples sepsis and otitis media.”
122. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-21 September 2015, San Diego, CA. Panelist in an interactive session entitled “I have a White Powder and Want a Drug: Shepherding New Compounds Across the Valley of Death.”
123. 36th American College of Toxicology Annual Meeting, 8-11 Nov 2015, Summerlin, NV. Keynote speaker with a lecture entitled “Enabling drug discovery & development to address the crisis of antimicrobial resistance: New tools, new pathways, & remaining challenges.”
124. Workshop on PK-PD for Antibacterial PK-PD, 12-13 Nov 2015, European Medicines Agency, London, UK. Team leader for EFPIA Antimicrobial Working Group Presentation team and presenter for discussion materials on “Replacing and Interpreting Clinical Data.”
125. 12th Annual DIA (Develop Innovate Advance) Japan, 15-17 Nov 2015, Tokyo Big Sight Ariake. Speaker with a lecture entitled “Evolution of the regulatory framework in the US and EU to support streamlined development of new antibiotics” in a session entitled “To Fight Against Superbugs - Future Development of Antibacterial Drugs Surrounding Drug-Resistant Pathogens.”
126. New Frontiers in Antibacterial Resistance Research, 20-21 Jan 2016, Stockholm. Speaker with lecture entitled “Overview of Challenges in the Conduct of Interventional Trials to Address Antibacterial Resistance.”

127. EU-US Collaboration on clinical trials related to antimicrobial resistance, 21-22 Jan 2016, Stockholm, Sweden. Keynote speaker with lecture entitled “Clinical research on AMR: Current pipeline, development issues, and ideas for ways forward”
128. 53rd Annual William J. Holloway Infectious Disease Symposium of the Medical Society of Delaware, May, 2016, Wilmington, DE. Lecture entitled “Enabling drug discovery & development to address the crisis of antimicrobial resistance: New tools, new pathways, & remaining challenges.”
129. DRIVE-AB mid-term congress on stimulating innovation, sustainable use, and global access to antibiotics, 2 June 2016, Amsterdam, The Netherlands. Panelist in a session entitled “New Economic models for antibiotic innovation”
130. FDA Public Workshop on Facilitating Antibacterial Drug Development for Patients With Unmet Need and Developing Antibacterial Drugs That Target a Single Species. July 18–18, 2016, Washington, DC. Speaker in session entitled “Challenges with Clinical Trial Design for a Drug Targeting a Single Species of Bacteria” with speaker and convenor for a session entitled “Developing narrow-spectrum agents: The example of Drug X-1.”
131. ESCMID-ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, 21–23 September 2016, Vienna, Austria. Plenary speaker with a talk entitled “Drug development within the context of AMR: giving new molecules the best chance”
132. ASM Conference on Antibacterial Development, December 11–14, 2016, Washington, DC. Speaker with lecture entitled “CARB-X and support for new tools for management of drug-resistant bacterial infections.”
133. FDA Public Workshop on Current State and Further Development of Animal Models of Serious Infections Caused by *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. March 1, 2017, Washington, DC. Speaker in session entitled “Challenges with Clinical Trial Design for a Drug Targeting a Single Species of Bacteria” with lecture entitled “Trial Design for Narrow-Spectrum Agents: Overview & Drug X-1.”
134. Solutions for Drug-Resistant Infections, 3-5 April 2017, Brisbane, Australia. Keynote speaker with lecture entitled “Developing new antibacterial products: Perspectives on giving new therapies the best chance.”
135. NIAID Workshop on PKPD for Development of Therapeutics against Bacterial Pathogens. June 14-15, 2017, Bethesda, MD. Program Committee and Session Co-Moderator for session entitled “Stakeholder feedback and discussion.”
136. National Academies of Medicine workshop on Combating Antimicrobial Resistance: A One Health Approach to a Global Threat – A Workshop. 20-21 June 2017, Washington, DC. Program Committee and speaker in a session entitled “Strengthening Partnerships and International Cooperation” with a talk entitled “Partnerships to combat AMR.”
137. ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, 6-8 September 2017, Boston, MA. Speaker with a talk entitled “DRIVE-AB – Driving Re-investment in R&D and Responsible Antibiotic Use.”
138. 8th Trends in Medical Mycology (TIMM-8), 6-9 October 2017, Belgrade, Serbia. Speaker with a talk entitled “F901318” in a session entitled “New antifungal drugs in the pipeline.”
139. Medicines Discovery Catapult Workshop: Next Generation Antibiotics, 16-17 Jan 2018, London, UK. Speaker with a talk entitled “Funding, Filing, & Finance” in a session entitled “Enabling Resources.”
140. Gordon Research Conference entitled “New Antibacterial Discovery & Development”, March 1-5, 2018, Ventura, CA. Invited speaker with a talk entitled “Predictions are difficult, especially when they are about the future: What should you consider as you place your bets for the next 10 years?”
141. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain, 21-24 April 2018. Speaker in a symposium entitled “Expediting antibacterial development: core lessons and key tools for a rocky road,” with a lecture entitled “Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?” Slides available at <http://amr.solutions/blog/eccmid-symposium-expediting-antibacterial-development-core-lessons-and-key-tools-for-a-rocky-road>.
142. 20th Congress of the International Society for Human and Animal Mycology, 30 June – 4 July 2018, Amsterdam, NL. Keynote lecture entitled “Antifungal drug discovery comes of age.”
143. 20th Congress of the International Society for Human and Animal Mycology, 30 June – 4 July 2018, Amsterdam, NL. Talk entitled “Antifungal pipeline session: F901318 - F2G.”
144. FDA Public Workshop on Development of Non-Traditional Therapies for Bacterial Infections. 21-22 Aug 2018, Washington, DC. Lectures entitled “Overview of non-traditional therapies” and “Case Study Z-3: Reducing risk of infection due to an MBL-producing organism by preventing acquisition of same.”

145. Gates Grand Challenges, Annual Meeting 15-18 Oct 2018, Berlin, Germany. Chair of a session entitled “Fostering cooperation: Incentivizing AMR R&D.”
146. Duke University, 2nd Annual Drug Discovery Symposium, 9-10 May 2019, Lecture entitled “Antifungal Drug R&D Comes of Age.”
147. 12th Berlin Conference on Life Sciences: Novel Antimicrobials and AMR Diagnostics, 14-15 Mar 2019 (Berlin), Chair of a session entitled “Update and progress report with regard to AMR innovations for human and animal health.”
148. International Course on Antibiotics and Resistance (ICARe), 19-26 Oct 2019, Annecy, France. Lecture entitled “New pathways to antibiotic registration.”
149. FDA-IDSA-NIH-Pew Public Workshop, 18-19 Nov 2019, Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States. Meeting co-organizer with lectures entitled “Antibiotic R&D 3.0: Let’s all row the boat together…” and “Meeting Summary”
150. Focus on Infection 2020, Royal College of Physicians of Ireland (7 Dec 2020): Lecture entitled “Antibiotics for Unmet Need: The Challenge of New Drugs for Bad Bugs.”
151. National Academies of Science, Engineering, and Medicine Committee on the Long-Term Medical and Economic Effects of Antimicrobial Resistance: Open Session workshop (5 Jan 2021) entitled The Antimicrobial Product Pipeline and Incentives for Market Viability. Lecture entitled “Pricing of Antibiotics and Proposals to Strengthen the Pipeline.”
152. Medical Research Council (UK) and The University of Exeter Strategic Workshop (4 May 2021): Drivers of Antifungal Resistance. Lecture entitled “Antifungal Drug R&D Comes of Age”
153. Royal Society of Medicine Antimicrobial Innovation Workshop (5 July 2021). Lecture entitled “The future of AMR reimbursement: What types of products will succeed?”
154. Best Brains Exchange (Canada): 12-13 Oct 2021 Workshop entitled “Challenges in the Antimicrobial Business Model and Potential Incentives to Increase Access and Promote Innovation” with lecture entitled “Setting the Scene: Challenges in the Antimicrobial Business Model and Potential Incentives to Increase Access and Promote Innovation.”
155. International Course on Antibiotics and Resistance (ICARe), 16-24 Oct 2021, Annecy, France. Lecture entitled “New pathways to antibiotic registration.”
156. ASM-ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance (7-9 Dec 2021 (virtual). Program Committee and Lecture entitled “Clinical Trials – Limits on the Kind of Data that Can be Generated and Why Superiority is So Hard.”
157. Mycoses Study Group Education and Research Consortium: 25 Jan 2022 Workshop (virtual) entitled “Novel Antifungal Therapies and Stewardship” with lecture entitled “(Regulatory) Landscape for Antifungal Drug Development.”
158. 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Lisbon, Portugal, 23-26 April 2022. Speaker in a symposium entitled “A moment to reset: Harnessing learnings to tackle antimicrobial resistance.” with a lecture entitled “A moment to reset: The economics of antibiotics: The pipeline is almost empty... why?”
159. NIAID Virtual Workshop: Strategies for Early-Stage Programs Developing Novel Antibacterial and Antifungal Drugs, 22-23 June 2022. Keynote lecture entitled: “Strategies for Early R&D: Plumbing, Phase 3, and Durable Value.
160. International Course on Antibiotics and Resistance (ICARe), 15-23 Oct 2022, Annecy, France. Lecture entitled “(New) Pathways to Antibiotic Registration.”
161. NASEM (National Academies of Science, Engineering, and Medicine) Workshop: The Impact and Control of Valley Fever, 17-18 Nov 2022. Speaker in a session entitled “Current patient management” with a talk entitled “Developing Therapies for Coccidioidomycosis: A Developer’s Perspective.”
162. 7th AMR Conference, 16-17 Mar 2023 (Basel): Speaker in a session entitled “Antifungals” with a talk entitled “The Challenge of Developing New Antifungal Agents for Invasive Fungal Infections.”
163. 7th AMR Conference, 16-17 Mar 2023 (Basel): Speaker in a session entitled “Improving the chance of success of clinical trials in unmet medical need populations” with a talk entitled “Improving the chance of success of clinical trials in unmet medical need populations.”
164. ASM-ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance (19-22 Sep 2023 (Boston). Lecture entitled “Complexities of Antifungal and Antibacterial Clinical Programs, Case Study: The example of Olorofim.”
165. International Course on Antibiotics and Resistance (ICARe), 7-15 Oct 2023, Annecy, France. Lecture entitled “(New) Pathways to Antibiotic Registration.”

14 March 2025

166. 10th Nikkei FT Communicable Diseases Conference: Speaker with a talk entitled “The importance of (new) antibacterial and antifungal drugs: Why don’t we have the drugs we need?”
167. Global Coalition on Aging (GCOA) and the Infectious Disease Society of America (IDSA): 15 Feb 2024 (virtual): Discussant during a webinar entitled “AMR Preparedness Index: 2024 Progress Report.”
168. Uppsala Antibiotic Days Conference, 28-29 May 2024, Uppsala, Sweden. Keynote speaker with talk entitled “The Economics of Antibiotic Discovery and Development.”
169. BIO International Convention, 3-6 Jun 2024, San Diego, CA. Panelist in a program entitled “Let’s Go STEDI: Moving Beyond QALYs to Understand the True Value of Antimicrobials and Vaccines.”

Commented [Rex24]: If you add, adjust summary counts above. This comment is attached to a single space at the end of the last reference. Insert new text before this space.